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ABSTRACT 
Advances in Down syndrome (DS) research depend on the availability of mouse 
models that replicate the genetic landscape and resulting phenotypes of DS which allow 
for experimental manipulation to correlate cellular and molecular changes with behavior, 
in a way that is not possible with human studies alone. These models have been a critical 
component in understanding the underlying mechanism of the intellectual disability in 
people with Down syndrome. The Ts(1716)65Dn (Ts65Dn) mouse is one of the most 
commonly used models as it recapitulates many of the phenotypes seen in individuals with 
Down syndrome, including neuroanatomical changes and impaired learning and memory. 
Although Ts65Dn exhibits a number of traits also present in DS, studies have produced 
variable results across time that call into question the validity of Ts65Dn and its use as a 
tool for studying Down syndrome. As Ts65Dn is the platform employed to gather 
preclinical evidence for treatments of DS, a critical assessment regarding the validity of 
the model over time is necessary. In this study, we conduct a rigorous and comprehensive, 
comparative analysis of multiple cohorts from the Ts65Dn line to assess the stability and 
reproducibility of neuroanatomical and behavioral characteristics. We measured gross 
anatomical brain and body size, neuronal density in the hippocampus and cerebellum, 
 
 viii 
alterations to oligodendrocyte maturation and myelination, acquisition of developmental 
milestones, and learning and memory performance using the Morris water maze. Our 
results show a significant amount of variability in Ts65Dn, both across as well as within 
cohorts. Inconsistent phenotypes in Ts65Dn mice highlight specific cautions and caveats 
for use of these mice when studying Down syndrome and suggest it is not always the most 
appropriate model system to use. In addition to phenotypic variability, a major pitfall of 
the Ts65Dn model is the unintended triplication of 60 non-DS-related genes and the 
unknown consequences on resulting phenotypes. Recent advances in gene editing 
strategies have allowed for the gene dosage normalization of those 60 genes and the 
generation of a new mouse model of Down syndrome, Ts66YAH. As this newly developed 
line has not yet been characterized, we conducted an analysis complimentary to our study 
of Ts65Dn to investigate the utility of Ts66YAH for Down syndrome research. We found 
Ts66YAH mice show no measurable neuroanatomical changes, developmental delays, or 
learning and memory deficits suggesting that the deleted non-DS-related genes do 
influence the phenotypes seen in Ts65Dn. Although Ts66YAH is a more genetically 
representative model of Down syndrome compared to Ts65Dn, it does not exhibit disease 
relevant phenotypes and therefore, may not be a suitable model for studying DS. The 
various downfalls identified in the present study may be impacting other mouse models of 
DS as well and thus, our analysis of Ts65Dn across time and comparative study of 
Ts66YAH illustrate the need for careful use and increased rigor to ensure translational and 
reproducible results when working with all mouse models of Down syndrome.   
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Clinical features of Down syndrome 
Genetic causes and consequences of Down syndrome  
Down syndrome (DS) is the most common genetic cause of intellectual disability, 
occurring in 1 out of 700 live births in the United States (Mai et al., 2019). Down syndrome 
was originally described by John Langdon Down in the mid-1800s (Down, 1866) but the 
underlying etiology of DS was not understood until almost 100 years later. It is now known 
that the cause of most DS cases is the triplication of human chromosome 21 (HSA21) 
(Lejeune et al., 1959; Hsu, 1998; Shin et al., 2010; Morris et al., 2012). Containing 400-
600 genes, of which only 200-300 are protein coding, HSA21 is the smallest human 
autosome (Hattori et al., 2000; Sturgeon and Gardiner, 2011). Profiling of differentially 
expressed (DEX) genes from HSA21 in DS has identified broad classes of biological 
processes that are affected in DS based on altered gene expression. Some of the processes 
affected in people with DS are related to immune system function, cytoskeletal structure, 
cell cycle and proliferation, vesicle trafficking, gene expression and chromatin regulation, 
and cell signaling (Lockstone et al., 2007; Antonarakis, 2017).  
Despite the small size of HSA21, trisomy 21 impacts gene expression throughout 
the entire human genome (Vilardell et al., 2011; Olmos-Serrano et al., 2016a; Letourneau 
et al., 2014; Mao et al., 2003, 2005; Lockstone et al., 2007). Expression of genes on HSA21 
is upregulated throughout the body in trisomy 21 (Mao et al., 2003) with 10-20% of HSA21 
genes being differentially expressed in the dorsal frontal cortex and cerebellum compared 




HSA21 has a greater proportion of its respective genes dysregulated in DS, the majority of 
DEX genes in the DS brain are located on other chromosomes (Olmos-Serrano et al., 
2016a) suggesting global disruption of gene expression due to trisomy 21. This widespread 
effect of HSA21 triplication on transcriptional networks may be why DS impacts multiple 
systems throughout the body and throughout life.  
Although HSA21 is the smallest autosome, the triplication of these genes results in 
a wide array of phenotypes. Individuals with DS are known to have congenital heart defects 
(Ferencz et al., 1989; Freeman et al., 1998), gastrointestinal problems (Levy, 1991; Torfs 
and Christianson, 1998), increased risk of childhood leukemia (Hasel et al., 2000; 
Wechsler et al., 2002), and craniofacial abnormalities (Frostad et al., 1971; Richtsmeier et 
al., 2002). Additionally, intellectual disability is a fully penetrant characteristic of Down 
syndrome. These cognitive deficits range in severity and can result in delayed cognitive 
development, impaired executive function, and alterations in speech and language 
capabilities (Chapman and Hesketh, 2000).  
Cognitive changes in Down syndrome 
The cognitive deficits present in Down syndrome begin at birth and persist 
throughout adulthood. Infants with Down syndrome are delayed in the acquisition of the 
developmental milestones related to motor and sensory development (Malak et al., 2015; 
Connolly et al., 1993; Haley, 1989; Palisano et al., 2001; Hartley, 1986; Matson et al., 
2010; Horovitz and Matson, 2011; Cardoso et al., 2015). These delays are in part due to 
hypotonia that adversely affects motor strength and muscle reflex development (Morris et 




can also lead to delayed acquisition of verbal and non-verbal language skills early on in 
life (Chapman et al., 1991, 1998; Lynch et al., 1995; Mundy et al., 1995, 1988; Caselli et 
al., 1998). These initial delays in motor and language capabilities can be compounded by 
hearing loss, speech motor dysfunction, and coordinated speech movement difficulties that 
are commonly found in people with DS (Roizen, 2007; Miller and Leddy, 1998; Stoel-
Gammon, 1997). Together, all of these deficits can contribute later to intellectual disability. 
During adolescence and adulthood, people with Down syndrome continue to 
demonstrate impaired cognitive abilities. The average intelligence quotient (IQ) for 
individuals with DS ranges from 25-55 compared to 90-110 in the general population 
(Bennet and Sells, 1979; Rynders and Horrobin, 1990). During childhood, weakness in 
executive functioning, working memory, and set shifting skills widen the gap in mental age 
between children with DS and typically developing children (Lanfranchi et al., 2010). 
Additionally, children and adolescents with Down syndrome demonstrate long-term and 
episodic memory impairments, suggesting hippocampal dysfunction early in life 
(Carlesimo et al., 1997; Pennington et al., 2003).  
These changes persist as individuals with DS age specifically showing weakness in 
verbal short-term memory, general long-term memory, and allocentric spatial learning, 
while visuo-spatial memory remains relatively intact (Jarrold et al., 2006; Lavenex et al., 
2015; Marcell and Armstrong, 1982; Carlesimo and Vicari, 1997; Jarrold et al. 2007; 
Vicari et al., 2005). Lastly, individuals with Down syndrome have an increased likelihood 
of developing dementia that resembles Alzheimer’s disease (AD) (Holland et al., 2000; 




and neurofibrillary tangles, is present in the brains of people with Down syndrome by 40 
years of age (Wisniewski et al., 1985; Zigman et al., 2002; Davidson et al., 2018) and this 
is thought to be due, in part, to the triplication of App, which is located on HSA21 (Prasher 
et al., 1998). The developmental delays and intellectual disability in Down syndrome are 
thought to be rooted in abnormal brain development and neuroanatomical alterations. 
Studies using human tissue and imaging strategies have uncovered various underlying 
mechanisms that may be the basis for the neurological characteristics seen in people with 
Down syndrome.  
Underlying neuropathology of Down syndrome  
The cognitive deficits experienced by people with Down syndrome are rooted in 
altered neurological development. In utero imaging studies have identified reduced brain 
weight and microcephaly in fetuses with Down syndrome (Guilhard-Costa et al., 2006) 
and in particular, reduced volumes of the developing hippocampus and cerebellum (Raz et 
al., 1995; Guidi et al., 2008, 2011). These early embryonic volumetric changes are due to 
reduced proliferation in the germinal zones and developing dentate gyrus that result in 
hypocellularity of these regions later in life (Contestabile et al., 2007; Guidi et al., 2008, 
2011).  
After birth and into adulthood, the DS brain continues to be smaller in overall size 
compared to age-matched brains with marked decreases in the volume of the frontal, 
occipital, and temporal lobes, as well as the hippocampus, amygdala, and cerebellum 
(Pinter et al., 2001; Kates et al., 2002; Smigielska-Kuzia et al., 2011; Carducci et al., 2013). 




reduced neuronal densities as well (Sylvester, 1983; Schmidt-Sidor et al., 1990; 
Wisniewski, 1990). The decreased size and hypocellularity of these regions involved in 
executive functioning, episodic memory, and long-term memory may contribute to the 
cognitive impairment seen in DS (Pennington et al., 2003; Raz et al., 1995; Menghini et 
al., 2011; Carlesimo et al., 1997). In addition to structural alterations, the brains of people 
with Down syndrome also display changes in synaptic and functional connectivity. 
Specifically, there are fewer synapses and decreased dendritic arborizations into adulthood 
in people with DS (Becker et al., 1986; Takashima et al., 1989). Functional connectivity 
measures using magnetic resonance imaging (MRI) of young adults with Down syndrome 
show low connectivity between the executive functioning networks that include the dorsal 
prefrontal and anterior cingulate cortices (Pujol et al., 2015). While these changes at both 
the cellular and system levels are associated with the cognitive deficits in Down syndrome, 
the etiology and precise mechanisms behind them are unknown.  
Individuals with Down syndrome have atypical myelination patterns as well. 
Myelin is an insulating sheath, formed by oligodendrocytes, that wraps around axons to 
facilitate efficient neural communication. As early as 37 weeks gestation, trisomic fetuses 
have fewer myelinated fibers resulting in delayed formation of myelin after birth 
(Wisniewski and Schmidt-Sidor, 1989; Wisniewski, 1990; Ábrahám et al., 2012). The 
neocortex, temporal lobe, hippocampus, and corpus callosum continue to be under-
myelinated throughout life (Wisniewski and Schmidt-Sidor, 1989; Dambaska and Laure-
Kaminonwska, 1990; Ábrahám et al., 2010; Olmos-Serrano et al., 2016a), specifically 




(MAG), and 2’3’-cyclic nucleotide-3’-phosphodiesterase (CNPase) (Banik et al., 1975; 
Palminiello et al., 2008; Vloklinský et al., 2001; Palo and Savolainen, 1973; Olmos-
Serrano et al., 2016a). Additionally, the lattice-like structure of myelinated fibers normally 
present in the brain (Wedeen et al., 2012) is not seen in DS (Olmos-Serrano et al., 2016a). 
The reduced complexity of myelination, in combination with hypocellularity of numerous 
brain regions and perturbed synaptic and electrophysiological properties, profoundly alters 
neuronal communication, exacerbating the cognitive deficits in Down syndrome.  
Advances in research using post-mortem human tissue and imaging have allowed 
us to understand the multifaceted underpinnings that contribute to DS phenotypes. 
However, even with this advanced knowledge, the exact etiology of DS is largely unknown 
and there are still no pharmacological therapeutics available to treat the neurological 
consequences of Down syndrome. Mouse models have been developed to replicate both 
the genetic and behavioral components of DS. With these models, DS research is able to 
assess the relationship between gene dosage imbalance and aneuploidy, the resulting 
neuropathology, and behavioral changes with the hope of identifying targetable approaches 
in order to develop treatments to improve the quality of life for people with Down 
syndrome. These models should uniformly and reliably reproduce the robust characteristics 
of DS pathophysiology that are most common to people with DS.  
Mouse models of Down syndrome 
Genetics of Down syndrome mouse models 
A number of mouse models exist that imitate various aspects of Down syndrome, 




been placed on these models by the field to advance our knowledge of the underlying 
genetics and mechanisms of DS. Mouse model engineering is based on the conservation of 
HSA21 genes in mice. There are orthologous regions on mouse chromosome (MMU) 10, 
16, and 17 that correlated to portions of HSA21. Due to extensive gene mapping efforts, it 
is known that approximately 39 HSA21 homologs are located on MMU10, 119 on 
MMU16, and 19 on MMU17 (Figure 1; Pletcher et al., 2001; Sturgeon and Gardiner, 2011; 
Aziz et al., 2018; Das and Reeves, 2011; Waterson et al., 2002).  
The earliest mouse model of DS was Ts16. This model was due to a naturally 
occurring Robertsonian translocation that produced a mouse that was trisomic for the entire 
length of MMU16 (Figure 2B; Gropp et al., 1975). The Ts16 line was widely used to study 
the underlying mechanisms of DS and early advances in understanding were credited to 
this model (Reeves et al., 1986; Haydar et al., 1996). However, several disadvantages 
existed to using Ts16. Due to the nature of the translocation, all genes on MMU16 were 
triplicated in Ts16 mice. MMU16 has regions that are syntenic to HSA21, but also regions 
of homology to human chromosomes 3, 8, and 16, (Gardiner et al., 2003; Sérégaza et al., 
2006; Mural et al., 2002). Thus, some phenotypes evident in these mice could be due to 
the effects of non-HSA21 gene triplication. Additionally, Ts16 mice did not survive after 
birth, making postnatal studies unobtainable, but the generation of this line was the first 
pioneering effort in constructing genetically representative models of DS.  
The Ts(1716)Dn mouse, referred to as Ts65Dn, was generated in 1990 using 
irradiation that resulted in a reciprocal translocation of the distal portion of MMU16 onto 




for ~104 MMU16 genes that are homologous to HSA21 and are triplicated in Down 
syndrome, spanning Mrp139 to Znf296, as well as 60 genes from the centromeric region 
of MMU17 that are not syntenic to HSA21 (Figure 2C; Sturgeon and Gardiner, 2011; 
Duchon et al., 2011). Although the role of these additional non-DS-related genes on 
resulting phenotypes is largely unknown, the Ts65Dn model offered the field great 
advantages to the previous Ts16 model as Ts65Dn animals survived postnatally and were 
more genetically similar to DS, despite the erroneous triplication of the MMU17 genes.  
Several other models of DS exist that were generated utilizing the syntenic 
segments of MMU16. To combat the confounding problem of the 60 non-DS-related genes 
triplicated in the Ts65Dn model, the Ts[Rb(12.1716)]2Cje (Ts2Cje) mouse was developed 
that carries the same region of MMU16 triplicated in Ts65Dn translocated onto MMU12, 
resulting in the triplication of ~104 genes from MMU16 but without the additional MMU17 
genes or the extra chromosome (Villar et al., 2005). Although these animals have a large 
triplicated segment of MMU16, they do not contain an extra chromosome. A similar model, 
Ts1Cje, is partially trisomic for MMU16, carrying 71 genes from Sod1 to Znf295 that are 
translocated onto the telomeric region of MMU12 (Figure 2D; Sago et al., 1998). Ts1Cje 
has a smaller number of triplicated genes and, like Ts2Cje, does not carry an additional 
freely segregating chromosome. Both Ts1Cje and Ts2Cje models demonstrate some DS-
like phenotypes (Villar et al., 2005; Siarey et al., 2005; Olson et al., 2007; Aziz et al., 
2018) however, neither is as frequently studied in DS research due to shortcomings in the 




The Down syndrome critical region (DSCR), located on the distal end of the long 
arm of HSA21, contains many of the chromosome’s gene-transcription sites and the 
triplication of this region is thought to be responsible for the phenotypes seen in Down 
syndrome (Korenberg et al., 1994; Sinet et al., 1994; Shapiro, 1999). However, this 
concept has been debated. To assess the role of the DSCR, the Ts1Rhr mouse was created 
which is trisomic for 33 genes of the DSCR (Olson et al., 2004). Characterization of this 
model showed that triplication of the DSCR was sufficient to produce some phenotypes of 
DS in the mice, but not all (Olson et al., 2004, 2007; Belichenko et al., 2009). 
The Dp(16)1Yey/+ (Dp16) mouse model was made using Cre-mediated 
recombination and has the full region of MMU16 that is syntenic to HSA21 added to the 
distal region of the endogenous MMU16 (Figure 2E), triplicating about 119 genes from 
Lipi to Zfp295 (Li et al., 2007). This model has the largest amount of triplicated HSA21 
orthologs and does not have any non-DS-related gene alterations. Dp16 mice have 
craniofacial abnormalities and behavioral deficits in adulthood, similar to those seen in 
people with Down syndrome (Yu et al., 2010b; Starbuck et al., 2014; Aziz et al., 2018). 
However, they show no deficits in prenatal brain development, as seen in Ts65Dn 
(Goodliffe et al., 2016; Aziz et al., 2018).  
In addition to the Dp16 model, that is partially trisomic for the entire syntenic 
region on MMU16, there are two lines, Dp(10)1Yey/+ and Dp(17)1Yey/+ that are trisomic 
for all the HSA21 orthologs that are on MMU10 and MMU17, respectively (Yu et al., 
2010a, 2010b). These two lines were cross-bred with Dp16 mice to develop the 




syntenic regions from MMU10, 16, and 17 (Figure 2F; Yu et al., 2010a). 
Dp(10)1Yey/+Dp(16)1Yey/+Dp(17)1Yey/+ is the most accurate genetic mouse 
representation of human Down syndrome and exhibits many phenotypes of DS including 
impaired learning and memory, reduced hippocampal long-term potentiation (LTP), and 
altered neuroanatomy (Yu et al., 2010a). However, even with a larger genetic similarity to 
Down syndrome, the triple trisomic Dp(10)1Yey/+Dp(16)1Yey/+Dp(17)1Yey/+ mice do 
not display all phenotypes seen in Ts65Dn mice.  
While most mouse models of Down syndrome rely on genetic manipulations of the 
HSA21 syntenic portions of MMU10, 16, and 17, some models have been developed that 
are transchromosomal. Tc1 mice carry a copy of human chromosome 21 (O’Doherty et al., 
2005). Although these animals are mosaic, meaning the human chromosome is not present 
in all cells throughout the body, they exhibit neuroanatomical changes, reduced LTP, 
impaired learning and memory capabilities, and heart defects (O’Doherty et al., 2005) 
similar to those seen in people with Down syndrome. The issue of mosaicism in Tc1 mice 
was overcome by utilizing mouse artificial chromosome vectors (MACs) to insert a full 
copy of HSA21, generating the TcMAC21 humanized mouse model (Kazuki et al., 2019). 
These mice show congenital heart defects, craniofacial changes, reduced body weight, 
smaller cerebellar volume, and deficits in learning and memory (Kazuki et al., 2019).  
Although numerous models of DS exist, Ts65Dn is most commonly studied and 
has been extensively characterized as it was the first model to survive postnatally, contains 
a large number of DS-related triplicated genes, and carries an extra freely segregating 




al., 2012). In addition to being a representative model of DS genetically, Ts65Dn also 
displays many phenotypic similarities to individuals with Down syndrome.  
Ts65Dn as a model of Down syndrome  
 Ts65Dn is the most frequently studied model of DS and has been shown to 
recapitulate many of the features seen in people with Down syndrome. During fetal 
development, Ts65Dn mice show delayed neocortical expansion that is due to a reduced 
proliferative capacity of neural precursor cells. This results in a thinner developing pallial 
wall and a decrease in overall brain size (Chakrabarti et al., 2007; Aziz et al., 2018; Shaw 
et al., 2020). After birth, trisomic mice have a reduced body and brain size that continues 
into adulthood (Roper et al., 2006; Bianchi et al., 2010; Costa et al., 2010; Shaw et al., 
2020). Postnatal brain morphology of Ts65Dn mice shows similar craniofacial 
abnormalities that result in a smaller head and brain, but specifically, a shortening of the 
rostro-caudal length that results in a brachycephalic brain (Richtsmeier et al., 2000; Shaw 
et al., 2020). More detailed assessment of the Ts65Dn brain shows comparable 
neuroanatomical alterations to those seen in people with DS. Ts65Dn mice have reduced 
hippocampal and cerebellar volumes as well as altered neuronal densities in these areas 
(Baxter et al., 2000; Lorenzi & Reeves, 2006; Insausti et al., 1998; Kurt et al., 2004; Olson 
et al., 2004; Roper et al., 2006) that may underlie learning and memory deficits as well as 
motor dysfunction. In addition to reduced neuronal densities, the number and structure of 
synapses and spine morphology are different in Ts65Dn; neocortical pyramidal neurons 
are reduced in length and have less dendritic arborization and spine density (Dierrsen et 




display abnormal morphologies with larger heads and shorter neck lengths (Belichenko et 
al., 2004, 2007). Synapse numbers are also decreased in the hippocampus and neocortex 
of Ts65Dn (Chakrabarti et al., 2007; Ayberk Kurt et al., 2004; Popov et al., 2011). Not 
only are the number of synapses reduced, the distribution of excitatory and inhibitory 
synapses is skewed, with there being more inhibitory synapses in Ts65Dn (Ayberk Kurt et 
al., 2000, 2004). The changes in neuron numbers and morphology may influence synaptic 
plasticity and abnormal electrophysiological properties seen in Ts65Dn. LTP capacity is 
reduced in the CA1 and dentate gyrus in trisomic mice while long-term depression (LTD) 
is increased (Siarey et al., 1997, 1999; Kleschevnicov et al., 2004). Alterations to LTP and 
LTD processes may influence the learning and memory deficits in Ts65Dn mice. Taken 
together, the disruptions to neuronal structure and function alter the physiological 
properties in the Ts65Dn brain and can contribute to cognitive impairments. 
Lastly, studies have shown that, like in the brains of people with DS, Ts65Dn mice 
have reduced levels of myelin protein throughout the brain less myelination in the cortex 
(Olmos-Serrano et al., 2016a). Additionally, the myelin wrapped around axons of the 
corpus callosum is thinner compared to euploid controls (Olmos-Serrano et al., 2016a). 
The reduction in myelin contributes to slower action potential conduction velocity across 
the corpus callosum in Ts65Dn (Olmos-Serrano et al., 2016a). These changes to myelin 
structure and function can slow neural communication and negatively impact cognitive 
abilities. 
 Just as in people with Down syndrome, the widespread neuroanatomical changes 




impairments present in these mice. Ts65Dn mice are delayed in the acquisition of major 
motor and sensory developmental milestones in early life (Holtzman et al., 1996; Toso et 
al., 2008; Olmos-Serrano et al., 2016b; Aziz et al., 2018; Shaw et al., 2020).  In adulthood, 
Ts65Dn demonstrate significant learning and memory deficits. Their performance on the 
Morris water maze (MWM), Y-maze, elevated T-maze, novel object recognition tasks, and 
contextual fear conditioning are all impaired (Olmos-Serrano et al., 2016b; Costa et al., 
2010; Reeves et al., 1995; Coussons-Read and Crnic, 1996; Escorihuela et al., 1998; 
Fernandez and Garner, 2008; Martinez-Cue et al., 2002) suggesting significant spatial 
learning difficulties and hippocampal dysfunction. Additionally, trisomic mice have poor 
motor coordination and balance which could be the result of hypocellularity in the 
cerebellum (Costa et al., 1999). The combination of cellular and behavioral changes 
documented in the Ts65Dn mice mirror many of the phenotypes known about Down 
syndrome, making it a representative model of the human condition.   
Although the Ts65Dn mouse model demonstrates many similarities to the traits 
seen in people with Down syndrome, there are limitations to its use. First, the translocation 
of the syntenic region of MMU16 on MMU17 resulted the triplication of ~60 genes from 
MMU17 that are not triplicated in people with DS (Figure 2C; Duchon et al., 2011; 
Reinholdt et al., 2011). These genes are known to have functions related to cytoskeletal 
structure, protein transportation, membrane fraction, and ion binding (Duchon et al., 2011). 
However, the role these genes play in the manifestation of DS-like phenotypes in Ts65Dn 




mice may be observing the effects of these genes being triplicated, not the effects of trisomy 
21 directly.  
Secondly, the originally developed Ts65Dn mice (Davisson et al., 1990) carried a 
mutation in the Pde6b allele that caused retinal degeneration (Keeleer, 1924). This made 
postnatal behavioral studies difficult as it required screening each animal for blindness. 
However, this mutation was corrected for, generating two separately maintained lines of 
Ts65Dn: the original 1924 line that carries the mutation and the congenic 5252 line that 
does not. The originally developed 1924 line of Ts65Dn (Davisson et al., 1990) was bred 
on an F1 hybrid background that was a cross between a C57BL/6JEi and C3H/HeSnJ (F1 
Hybrid) and contained a mutation in the Pde6b allele carried by the C3H/HeSnJ 
background. These mice were prone to developing retinal degeneration, making post-natal 
behavioral studies difficult with the 1924 line. To address this problem, a new stock of 
Ts65Dn animals, the 5252 line, was developed that contains only the wildtype allele of 
Pde6b. This was achieved by backcrossing C3A.BLiA-Pde6b+/J animals that carried the 
wildtype allele for Pde6b with C3H/HeSnJ animals for 10 generations (Costa et al., 2010). 
This produced a congenic C3H/HeSnJ line that could then mated with Ts65Dn animals. In 
this way, the 5252 line is also maintained on a B6EiC3H F1 Hybrid background to avoid 
changes in behavioral phenotypes due to genetic background, but do not carry the mutation 
resulting in blindness. Although these two lines are supposedly genetically identical, except 
for the Pde6b mutation, subtle differences between them may exist as the backcrossing that 
was needed to produce the wildtype C3H/HeSnJ could have resulted in the 5252 line being 




line confirmed phenotypic similarities between 1924 and 5252 animals (Costa et al., 2010). 
However, the details of this genetic variation has never been assessed in the 1924 and 5252 
lines but could be a source of phenotypic differences between the lines seen elsewhere. 
Therefore, when studying DS using the Ts65Dn model, it is imperative to note which line 
of Ts65Dn is being used, as discrepancies in phenotypes have been noted between the lines 
(Shaw et al., 2020).  
Lastly, the breeding scheme for Ts65Dn is complex and exposed to selective 
breeding and unknown consequences due to wildtype background effects. The Ts65Dn 
lines, both 1924 and 5252, are maintained on a hybrid background that is a cross between 
C57BL/6JEi (B6Ei) and C3H/HeSnJ (C3H) strains (Figure 3). A mating between a B6Ei 
and a C3H produces offspring carrying half B6Ei alleles and half C3H alleles, referred to 
as B6EiC3H F1 Hybrids. The male F1 Hybrids are then bred to trisomic Ts65Dn females, 
producing litters with both euploid and trisomic pups. Only female Ts65Dn mice are fertile 
so female trisomic offspring are backcrossed to F1 hybrid males in the colony for breeding 
(Figure 3). Trisomic dams are prone to prenatal and perinatal loss and do not always 
provide sufficient maternal care (Roper et al., 2005). In this way, individual Ts65Dn 
colonies are subject to selective breeding by only backcrossing females that produce and 
care for litters. Readily breeding the most-fit dams within a colony could impact the 
phenotypic profile of an individual litter or an entire colony. Additionally, as Ts65Dn is 
maintained on an outbred hybrid background, the admixture of alleles could vary between 
litters, resulting in offspring that are not genetically identical. Trisomy 21 is a highly 




introducing genetic variability makes it more difficult to discern what phenotypes are the 
result of gene triplication and what effects are due to genetic variability from wildtype 
background. Although Ts65Dn is regularly used to study DS, these issues raise concerns 
about the effectiveness of Ts65Dn, especially as this model is most commonly used to 
gather preclinical evidence for pharmacological treatments in Down syndrome.  
Clinical importance of validated models of Down syndrome 
Despite being the most prevalent feature of Down syndrome, there are no 
pharmacological therapies available for the cognitive impairments in DS. Several drugs 
and compounds have been tested in Ts65Dn, with some showing cognitive improvement 
in the mice (Herault et al., 2017). LTP is reduced in the hippocampus of Ts65Dn, due in 
part to an excitatory-inhibitory imbalance (Siarey et al., 1999; Fernandez et al., 2007; 
Belichenko et al., 2007; Hanson et al., 2007; Kleschevnikov et al, 2004). Therefore, 
treatment with GABAA receptor antagonists could mitigate the learning and memory 
deficits that are caused by impaired LTP in the hippocampus. Treatment with GABAA 
receptor antagonists picrotoxin and pentylenetetrazole rescued learning deficits in Ts65Dn 
on novel object recognition tasks and MWM tests (Fernandez et al., 2007; Rueda et al., 
2008) suggesting that restoring the balance between excitatory and inhibitory inputs can 
diminish cognitive deficits in DS. Although results in Ts65Dn mice show learning and 
memory improvement with few negative side effects, pentylenetetrazole is a known 
convulsant. Children with DS have an increased risk of experiencing seizures (Arya et al., 
2011) and treatment with GABAA antagonists could exacerbate that risk thus, presenting a 




In addition to LTP being reduced in Ts65Dn, LTD is increased (Siarey et al., 1997, 
1999; Kleschevnicov et al., 2004). LTD weakens the strength of a synapse and can be 
influenced by the level of N-methyl-D-aspartate (NMDA) activity (Dudek and Bear, 1992; 
Mulkey and Malenka, 1992). Ts65Dn mice display increased NMDA-induced LTD in the 
hippocampus (Costa et al., 2008; Scott-McKean and Costa, 2011), thus, treatment intended 
to reduce NMDA-activity could normalize LTD in DS. Memantine is a NMDA receptor 
antagonist and has been shown to improve learning and memory capabilities in mouse 
models of AD (Lipton, 2007). Treatment with memantine in Ts65Dn improved learning 
and memory effects on contextual fear tasks and the MWM (Costa et al., 2008; Rueda et 
al., 2010) however, these improvements were not long-lasting and performance regressed 
to pre-treatment levels when memantine administration was discontinued (Lockrow et al., 
2011). Despite the short-term effects in Ts65Dn, a clinical trial of memantine (Namenda®) 
has shown to be safe and effective for improving cognitive abilities in people with Down 
syndrome and has completed a Phase 4 trial (clinicaltrials.gov/ct2/show/NCT01112683) 
and is currently being investigated in a follow-up trial 
(clinicaltrials.gov/ct2/show/NCT02304302).  
Another possible therapeutic avenue focuses on improving adult neurogenesis. 
Both people with DS and Ts65Dn mice have reduced neuronal density in the hippocampus 
(Pinter et al., 2001; Sylvester, 1983; Wisniewski, 1990; Lorenzi and Reeves, 2006; Insausti 
et al., 1998; Kurt et al., 2004), thus increasing rates of neurogenesis could restore cell 
numbers and potentially improve memory. Fluoxetine, a serotonin reuptake inhibitor, has 




Ts65Dn, treatment with fluoxetine increased neurogenesis in the hippocampus and 
improved cognitive performance on contextual fear conditioning tasks (Clark et al., 2006; 
Bianchi et al., 2010). However, other reports of fluoxetine treatment in Ts65Dn showed no 
behavioral improvements and significant adverse reactions including seizures and death 
(Heinen et al., 2012). Mixed findings of this treatment in mice demonstrate the 
complexities of treating the cognitive impairments in DS.  
While many candidate therapeutics have shown promising results in mice, few have 
gone on to be successful in human clinical trials. For example, antioxidant supplementation 
was shown in Ts65Dn to improve working memory (Lockrow et al., 2009) however, no 
cognitive difference was found when individuals with DS were treated with daily 
antioxidants (Lott et al., 2011). Even though the current clinical trials of memantine 
treatment have proven successful thus far, initial pilot trials testing memantine in people 
with DS showed no difference in expected outcomes of improved episodic and spatial 
memory (Boada et al., 2012) despite there being ample evidence in Ts65Dn. Additionally, 
Hoffman-La Roche began a clinical trial of a GABAA ɑ5 antagonist aimed at improving 
cognitive performance in people with Down syndrome 
(clinicaltrials.gov/ct2/show/study/NCT02024789). In spite of the positive effects of GABA 
antagonists seen in Ts65Dn (Fernandez et al., 2007; Rueda et al., 2008), the clinical trial 
was terminated in Phase II due to a lack of efficacy on primary endpoints, again 
demonstrating a lack of translatability between mouse models and successful human 




Although Ts65Dn has greatly improved our understanding of the cellular, 
molecular, and physiological deficits in Down syndrome, the failure rate seen amongst 
clinical trials for Down syndrome could be due to the validity of the mouse model used to 
gather supporting preclinical evidence. Results found using Ts65Dn that have informed 
preclinical trials are based on the assumption that the mechanisms responsible for DS-like 
phenotypes in the mouse are the same as those causing the human phenotypes. The 
triplication of HSA21 impacts gene expression across the genome and, while there are 
conserved and orthologous genes between the mouse and human that are triplicated in 
Ts65Dn, species-specific effects of trisomy may produce divergent phenotypes. Also, the 
genetic construction of Ts65Dn resulted in the triplication of non-DS-related genes that 
could impact the specific features seen in the mice that are not present in people with Down 
syndrome, further confounding the use of this model. The validation of animal models in 
research is of critical importance as developing therapeutics that can curtail the extent of 
cognitive deficits of DS could provide greater quality of life and independence for 
individuals with Down syndrome.  
To determine the stability of phenotypes in Ts65Dn we have utilized rigorous 
metrics to evaluate multiple cohorts of Ts65Dn ranging from 2014 to the present, including 
a re-derived line of Ts65Dn (5252) reconstituted from cryogenic embryo stocks that were 
preserved early during the colony’s development at Jackson Laboratory. Individual cohorts 
are identified by the year that breeding founders were imported into our private colony 
(Figure 4). This work is the first comparative study of multiple iterations of both strains 




hippocampus and cerebellum, oligodendrocyte maturation, tested developmental milestone 
acquisition, and assessed spatial learning and memory using the same rigorous metrics and 
experimental procedures for each mouse colony. We found that Ts65Dn mice display 
different levels of phenotypic severity and that there is a large degree of variability and 
lability in the Ts65Dn line across generations (Figure 23, Table 2). Additionally, we have 
conducted the first characterization of a novel model of DS, the Ts66YAH mouse, and 
found these animals do not display any of the commonly found neurological features of 
DS such as microencephaly, delayed motor development, or learning and memory 
impairments. These results call into question the potential use and validity of the Ts65Dn 
and Ts66YAH models for studying aspects of neurological development in Down 
syndrome. Finally, we use these results to outline recommendations for future use and 





Fi gure 1. Comparative figure of HSA21 and mouse chromosomes 10, 16, and 17. 
A) Re gions of homology between HSA21 and the mouse genome which 






Figure 2. Schematic of mouse models of Down syndrome. A) Cartoon 
representation of homology between HSA21 and mouse chromosomes B-F) 
Images show the genetic composition of Ts16 (B), Ts65Dn (C), Dp(16)1Yey/+ 
(E), Ts1Cje (D), and Dp(10)+Dp(16)+Dp(17) (F) with regions of HSA21 










Figure 3. Ts65Dn breeding scheme. The Ts65Dn line is maintained on an F1 hybrid 
background (B6EiC3) which is a cross between a C3H/HeSnJ and a C57BL/6JEi. 
B6EiC3 males are then bred to trisomic females, producing litters that contain both 
euploid and trisomic pups. The trisomic females from a given litter are used to 
backcross into the existing colony’s breeding maintenance, as only female Ts65Dn 
mice are fertile.  
24 
Figure 4. Graphical depiction of the Ts65Dn timeline. Originally developed in 1990, 
Ts65Dn was the first mouse model of Down syndrome to survive postnatally. This line 
(noted as 1924) contained a mutation in the Pde6b
rd1
 gene that resulted in retinal 
degeneration. In 2010, Ts65Dn was corrected to contain only wild type Pde6b, 
preventing the recessive retinal degeneration present in the original animals. This line 
is referred to as 5252. Since 2010, both the 1924 and 5252 strains have been 
continuously breeding at Jackson Laboratories. The cohorts of animals analyzed in this 
paper are designated with their strain number and year the founder dams were imported 
from Jackson Laboratories and in-house colonies were established. The 5252
2014
 line 
was used to analyze white matter development, developmental milestones, and Morris 




MATERIALS & METHODS 
Animal care and use 
Different strains of the Ts65Dn mouse model of DS were purchased from The 
Jackson Laboratory (Bar Harbor, ME). These strains were B6EiC3Sn.BLiA-
Ts(1716)65Dn/DnJ (Ts65Dn; stock number 005252) or cryo-recovered B6EiC3Sn.BLiA-
Ts(1716)65Dn/DnJ specifically ordered from Annex 18 (Ts65Dn; stock number 005252). 
Ts65Dn and euploid littermates were generated by mating Ts65Dn female mice with 
B6EiC3Sn.BLiAF1/J (F1 hybrid; stock number 003647) males imported from The Jackson 
Laboratory (Bar Harbor, ME). Multiple different cohorts of Ts65Dn mice were imported 
from The Jackson Laboratory from 2014 to 2019. For clarity, the different colonies are 
named based on the Ts65Dn strain and time of importation (Figure 4): 52522014 (imported 
from Jackson Laboratories in 2014, strain 005252), 52522015 (Imported from Jackson 
Laboratories in 2015, strain 005252), 52522019 (imported from Jackson Laboratories in 
2019, strain 005252) and 5252Cryo2010 (Strain 5252 recovered in 2019 from cryo-preserved 
embryos frozen around 2010). Additionally, Ts66YAH animals were gifted to us from 
Yann Herault of the Institut de Génétique et de Biologie Moléculaire et Cellulair in France.  
Genotyping to confirm trisomy was done using genomic DNA from tail snips, using 
primers that have been previously described (Reinholdt et al., 2011). Trisomic primers: 
Chr17fwd-5’-GTGGCAAGAGACTCAAATTCAAC-3’ and Chr16rev-5’-
TGGCTTATTATTATCAGGGCATTT-3’. These primers produce a 275bp amplification 
product. Positive control primers: IMR8545-5’-AAAGTCGCTCTGAGTTGTTAT-3’ and 




Rosa locus. PCR cycle conditions were: Step 1: 95˚C for 2 mins; Step 2: 95˚C for 20 s; 
Step 3: 55˚C for 30s; Step 4: 72˚C for 45s (Step 2-4 repeated for 40 cycles); Step 5: 72˚C 
for 5 mins, followed by a 5 min extension at 72˚C and a 4˚C hold. Products of the PCR 
were separated on a 1% agarose gel. 
All murine experiments were conducted according to international ethical standards 
and approved by the Institutional Animal Care and Use Committees (IACUC) of Boston 
University and the NIH guide for the care and use of laboratory animals. All experimental 
animals were bred and housed in a pathogen free facility with weekly wellness assessments 
conducted by veterinary staff. Animals were housed in individually ventilated cages (IVC) 
with standard bedding and a nestlet square. Rodent chow and water were available ad 
libitum. The colony was maintained on a 12:12 light/dark cycle, with lights on at 07:00. 
For the developmental milestones, animals were housed with littermates & mother until 
weaning when they were then housed in cages of 3-5 animals, regardless of genotype. Two 
weeks prior to Morris water maze testing, all animals were separated into single cages and 
remained that way for the duration of the study. 
Tissue collection and processing 
Animals were anesthetized by intraperitoneal injection of a ketamine/xylazine 
cocktail and intracardially perfused with 4% paraformaldehyde (PFA) in 0.1M phosphate 
buffer saline (PBS, pH 7.4). Perfused brains were removed and post-fixed in 4% PFA 
overnight at 4˚C. Post-fixing, tissue was placed in 30% sucrose at 4°C until sunk then 
embedded in Tissue-Tek Optimal Cutting Temperature compound (OCT; Sakura). 




80°C or immediately sectioned in 16µm thick frozen sections using a Microm HM 550 
(ThermoFisher Scientific) which were mounted on Superfrost Plus slides (ThermoFisher 
Scientific). Slides were dried at room temperature then stored at -80˚C. 
Immunohistochemistry and quantification 
Slides containing the cut tissue were brought to room temperature and rehydrated 
in 1X PBS for 15 minutes. Slides were then washed three times in 1X PBS for five minutes 
each and incubated in a blocking solution comprised of 5% normal goat serum, 0.3% Triton 
X-100, and 1X  PBS for 2 hours at room temperature. This was followed by incubation in 
primary antibody overnight at room temperature. Slides were washed 3 times in 1X PBS 
and incubated with fluorescent appropriate secondary antibodies in blocking solution for 
2h at room temperature. Finally, slides were mounted in Vectashield with DAPI (Vector 
Laboratories). The following primary antibodies were used: rabbit anti-Oligodendrocyte 
Transcription Factor 2 (1:250) Millipore, AB9610), guinea-pig anti-NG2 (1:1000, gift 
from William Stallcup, Sanford Burnham Prebys Medical Discovery Institute, San Diego 
CA, RRID: AB_2314937), mouse anti-CC1 (1:500, CalbioChem OP80), rabbit anti-NG2 
(1:700, Millipore AB5320), mouse anti-O4 (1:200, R&D Systems RRID: AB_357617), 
mouse anti-O1 (1:200, R&D Systems RRID: AB_2314990), and mouse anti-NeuN (1:500, 
Millipore MAB377). Secondary antibodies were AlexaFluor 488-, 546-, 633-conjugated 
(1:250, Invitrogen).  
All sections were mounted with Vectashield with DAPI (Vector Laboratories) and 
imaged using a LSM710 confocal microscope (Carl Zeiss). For OLIG2+, CC1+, and NG2+ 




magnification and 16μm confocal z-stacks were analyzed using LSM software. Cell 
densities in the hippocampus and cerebellum were assessed by taking an average of five 
16μm z-stack confocal images at 20x magnification of the CA1 and CA3 of the 
hippocampus and lobule III, and IV/V of the cerebellum. Total number of NeuN+ cells 
were counted and normalized to volume of the image. 
Gene expression analysis and RT-qPCR 
Samples for gene expression analysis via quantitative reverse transcription 
polymerase chain reaction (RT-qPCR) were collected by anesthetizing mice with 
isoflurane prior to decapitation. The brain was extracted and the corpus callosum and 
cortex were collected individually and flash frozen. RNA was then isolated using the 
Qiagen RNeasy Mini Kit (cat.74104), cDNA was prepared following the protocol for 
SuperScript IV VILO Master Mix (ThermoFisher 11756050). RT-qPCR for MBP (Thermo 
Mm01266402) and MAG (Thermo Mm00487538) was done following the protocol for 
FastTaq Advanced Assays (ThermoFisher 4444557). Two housekeeping genes were used 
for all samples, Ppia and Actb. Analysis was completed using Bio-Rad CFX Maestro 
software to calculate fold change of target genes. Trisomic expression levels of MBP and 
MAG were normalized to the respective gene expression in euploid controls.  
Gross anatomical measurements 
Post-natal brains were imaged using an Olympus MVX10 microscope and 
measurements were made using Axiovision software (Zeiss). Cortical rostral-caudal 




cortical medial–lateral lengths were measured from the median longitudinal fissure to the 
maximal lateral aspect of the telencephalic hemisphere. 
Hind limb reflex 
The hind limb reflex was performed at postnatal day (P) 15, 21 at the end of the 
developmental milestones, P30, as well as at P60, prior to the start of the Morris water 
maze task. Animals were suspended by the base of the tail for a 5 second count and the 
degree of motor deficit in the hind legs was scored on a scale of 0 to 2. A normal extension 
reflex is given a score of 0, imbalanced extension or extension reflex in one limb as 1, and 
retraction of both limbs or the absence of extension reflex in both limbs is scored as 2. 
Developmental milestones 
Pups were tested on a set of neonatal behavioral assessments to measure developing 
sensory and motor skills which included: 1) body orienting and motor coordination (surface 
righting, air righting, and negative geotaxis), 2) strength (cliff aversion and forelimb grasp), 
3) sensory system development (rooting, auditory startle, ear twitch, and eye opening), 4) 
rotatory behavior in open field. All experimental procedures were performed between 
10:00 and 14:00 daily by the same experimenter, in a blind set up to avoid experimenter 
bias of genotype. At the start of the developmental milestone procedures, all pups were 
removed from parent housing to a clean cage. Pups were assessed one at a time and returned 
to the parental cage after task completion. Animals were tested daily between P0 and P21, 
with weight data collected at P0 and forelimb/hind limb tattoos made using a sterile needle 
filled with non-toxic green ink to identify individual pups throughout the course of the 




or absence of the given reflex. If a pup exhibited the reflex for two consecutive days, the 
milestone was scored as acquired and no longer tested in that pup on subsequent days. A 
developmental milestone (DM) score was calculated for each animal using the following 
formula: 1+(X-A)*(10-1)/B-A where X is the individual score, A is the lowest score, and 
B is the highest score for a given milestone. Males and females were evaluated separately 
therefore score ranges are based on each respective sex. These were then summed for each 
animal to generate a composite DM score. 
Morris water maze 
All behavioral testing was done during the light phase between 09:00 and 14:00. 
Morris water maze (MWM) testing was done to assess spatial learning. A white, 125cm 
diameter circular pool was filled with tap water and made opaque with the addition of non-
toxic water-based white paint (Crayola). Water temperature was kept at 25˚C to limit stress 
and hypothermia. Trials were videotaped and scored with Ethovision video tracking 
software (Noldus Actimetrics Inc., Wilmette IL). 
Animals that were tested in developmental milestones were aged to P60 for MWM 
behavior. The structure of the training schedule was as follows: cued trials (4 consecutive 
days), hidden acquisition trials (12 consecutive days), and probe trial (1 day). During the 
cued and acquisition phases, mice were tested in 4 trials per day with each trial beginning 
by placing the mouse into the water near the edge of the pool in one of the non-target 
quadrants. The start order was semi-random for each mouse, with a different start quadrant 
from the prior trial. During cued training, all visual cues were removed from sight to avoid 




was cued via a metal stick with a black ball atop and was placed pseudo-randomly in 
different locations across the trial days. After the completion of the cued learning phase, 
room cues made of cardboard with various shapes were placed on the walls surrounding 
the pool to facilitate spatial learning. During the hidden acquisition days, the platform 
remained in the same quadrant during all trials and the platform cue was removed. Mice 
were allotted 60 seconds to reach the platform. More than 60 seconds was scored as a failed 
trial, and noted as 61 seconds for analysis purposes. If the mouse failed to reach the 
platform, it was guided there by the experimenter. Once on the platform, the mouse 
remained there for 15 seconds before being removed from the pool and returned to the 
subject’s home cage, lined with absorbent paper towels. Parameters measured during the 
learning trials were latency to reach the platform, total distance swam, swimming speed, 
time per quadrant, and time spent in the periphery of the pool. 
A probe trial was tested after the completion of the hidden acquisition phase 
training. The probe trial was a single 60 second trial during which the platform had been 
removed from the pool. Mice were given 60 seconds to swim in the pool and time spent in 
each quadrant and number of crossings into the trained platform location were recorded. 
In vitro culture of OPCs 
Mouse oligodendrocyte precursor cells (OPCs) were cultured in mixed glial 
conditions and subsequently isolated according to the following parameters. Cerebral 
cortices were dissected from P0-P2 pups in cold HBSS containing 26mM HEPES, 0.3% 
glucose, and 0.75% sucrose, meninges removed, and dissociated with 0.05% trypsin with 




with 10% fetal bovine serum in DMEM. Tissue was triturated first with 5mL serological 
pipette, followed by 1000μL pipette tip, and finally a 200μL tip and filtered through 40μm 
cell strainer. Cells were counted with a Countess II FL (Life Technologies) and plated into 
poly-L-lysine coated T25 flasks with 5% FBS/1X PenStrep in DMEM. Cells were cultured 
for 7-10 days at 37˚C, 5% CO2, with media changes every 2-3 days until confluency. To 
assess the differences in OPC maturation between euploid and trisomic cells, all samples 
were collected and cultured in individual flasks while genotyping was performed, before 
being pooled together.  
To isolate OPCs from the mixed glial culture, flasks were shaken at 200rpm at 37˚C 
for 2-3 hours. Media was removed and fresh media was added. Cells incubated at 37˚C, 
5% CO2 for 1 hour and then returned to the shaker for 16-20 hours. Following the shake, 
supernatant from the flasks was removed an placed into an uncoated petri dish and 
incubated at 37˚C, 5% CO2 for 20-40 minutes with agitation every 5-10 minutes. At this 
stage, cells from individual samples were pooled by genotype. Supernatant was collected 
into a conical and spun at 1200rpm for 5 minutes and suspended in DMEM SATO base 
growth culture media (Emery and Dugas, 2013) with 20ng/mL of PDGF (Millipore 01-
310) and bFGF-2 (Millipore 01-106). Cells were then plated in 24-well format at 40,000 
cells/well on poly-L-lysine and laminin coated coverslips. The following day media was 
changed to remove PDGF and bFGF-2 and fresh DMEM SATO base media was added 
containing 40ng/mL of thyroid hormone T3 (Sigma T6397) to promote differentiation. 
OPCs were allowed to differentiate and mature for 72 hours in a 37˚C, 5% CO2 incubator 




Cells were stained with NG2, O4, and O1 to evaluate state of maturation after 72 
hours. Using the LSM710 confocal microscope, 5 representative fields were imaged to 
produce z-stacks from 2-3 wells per genotype. Cells were manually counted in LSM image 
browser software. This experiment was repeated with three biological replicates to generate 
data presented here. 
Statistical analysis 
All data collection was done under blinded conditions in which the experimenter 
was blinded to the genotype of each animal until analysis. Immunohistochemical and 
histology analyses were done using two-way unpaired Student’s t-tests to compare trisomic 
animals to their respective euploid controls. Developmental milestones were analyzed 
using two-way unpaired Student’s t-tests for comparisons of the average day of acquisition 
between genotypes and Fischer Exact tests for the acquisition per day. Variance was 
calculated for developmental milestones using ơ2 = Ʃ(x-μ)2/N. Morris water maze data was 
analyzed with repeated measures 2-way ANOVAs and post hoc Sidak multiple 
comparisons test. Normal distributions for behavioral tests were determined using 
D’Agosino K2 tests. Line graphs and bar graphs show mean ± SEM. Boxplots presented 
show the median ± Q1 and Q3 with individual data points overlaid. For all analyses, a P-








Gross body and brain measurements of Ts65Dn mice across generations 
Introduction 
 Individuals with Down syndrome have distinct physical characteristics which 
include smaller stature as well as specific craniofacial appearances. When compared to 
typically developing peers, children with DS have decreased growth rates throughout 
development, but specifically during infancy and adolescence (Cronk et al., 1988). 
Individuals with Down syndrome also have characteristic facial appearances that stem from 
dysmorphology of the developing craniofacial skeleton. These structural changes cause an 
overall reduced head size, specifically in the anterior-posterior length of the skull, resulting 
in brachycephaly (Richtsmeier et al., 2000; Farkas et al., 1985; Farkas et al., 1985; Frostad 
et al., 1971; Fischer-Brandies, 1988; Bagic & Verzak, 2003).  
The shape of the brain mirrors the brachycephalic nature seen in the skull shape of 
people with Down syndrome, with the anterior-posterior aspect being shortened. During 
gestation, there is a noticeable reduction in the frontal lobe length and an increase in trans-
parietal length (Guilhard-Costa et al., 2006; Bahado-singh et al., 1992; Winter et al., 2000) 
resulting in a smaller, rounded brain. Post-mortem analysis shows that brains from fetuses 
with Down syndrome are significantly smaller in terms of weight than age-matched 
controls (Guilhard-Costa et al., 2006) with specific volumetric reductions to hippocampal 
and cerebellar structures during embryonic development (Guidi et al., 2008, 2011). These 
anatomical changes are present after birth as well and persist into adulthood with the 




showing significant reductions in volume (Pinter et al., 2001; Kates et al., 2002; 
Smigielska-Kuzia et al., 2011; Carducci et al., 2013). These anatomical alterations are 
present throughout the lifespan and underlie the cognitive deficits in people with Down 
syndrome. 
 These hallmark features of DS have been documented in mouse models, 
specifically Ts65Dn, but with variable findings. Within the 1924 line of Ts65Dn, during 
embryonic development there is no change to overall body size but there is a decrease in 
the medial-lateral (M-L) length of the developing telencephalon (Chakrabarti et al., 2007), 
unlike what is noted in humans with Down syndrome. After birth, the 1924 line shows a 
reduced body weight continuously from birth until 5 months of age (Roper et al., 2006) as 
well as a decrease in total brain weight (Bianchi et al., 2010). Morphometric assessments 
of the craniofacial skeletal development in the 1924 line show a high degree of similarity 
between the craniofacial abnormalities in people with Down syndrome and Ts65Dn. 
Similar to what is seen in people with DS, these structural changes in mice result in an 
overall reduction in head size, specifically in the rostro-caudal (R-C) dimension but not the 
mediolateral aspect, causing brachycephaly (Richtsmeier et al., 2000).  
Contrary to prior assessments in the 1924 line (Chakrabarti et al., 2007), 
neuroanatomical analysis of the 5252 line during embryonic development shows a decrease 
in total crown-rump and R-C length, with no change to M-L length (Aziz et al., 2018; Shaw 
et al., 2020), suggesting inconsistencies between the 1924 and 5252 lines. However, since 
the development of the 5252 line of Ts65Dn, few studies have fully assessed the postnatal 




in body weight at 4-5 months of age (Costa et al., 2010). Likewise, Ts65Dn mice from the 
52522014 cohort show reduced body weight from P5 to P21 (Aziz et al., 2018) but there 
have been no comprehensive longitudinal characterization of the postnatal gross 
neuroanatomical changes in 5252 trisomic mice. To evaluate the permanence and stability 
of body and brain size differences in Ts65Dn, we measured body weight and telencephalon 
size of two cohorts of mice (5252Cryo2010 and 52522019) at various ages. While some cohorts 
of Ts65Dn have been shown to mimic gross anatomical changes seen in Down syndrome, 
our research shows inconsistencies in phenotypes across time in the Ts65Dn line.  
Results 
Changes in postnatal body weight and gross brain measurements 
The physical features of DS, such as smaller body stature and reduced brain 
volume, have been well characterized. The Ts65Dn mouse model historically has been 
shown to mimic many of these gross anatomical differences (Costa et al., 2010; Holtzman 
et al., 1996; Hill et al., 2007; Richtsmeier et al., 2000; Aziz et al., 2018; Costa et al., 2010). 
In the present work, Ts65Dn males from two different generations of the 5252 colony 
(5252Cryo2010 and 52522019) were assessed on overall body weight, rostral-caudal, and 
medial-lateral length of the telencephalon at P15, P30, and P60 (Figure 5). The analysis 
shows that 5252Cryo2010 mice are significantly lighter in terms of body weight compared to 
controls at P15 (n = 9, 7; p = 0.004) and P30 (n = 8, 7; p = 0.003) but this difference 
normalizes by P60 (n = 8, 8) (Figure 5A). Similarly, 52522019 mice show a significant 
decrease in weight at P15 (n = 19, 5; p = 0.005) and P30 (n = 10, 10; p < 0.001) compared 




In terms of gross brain measurements, the R-C length of 5252Cryo2010 mice is 
significantly shorter compared to controls at both P15 (p = 0.005) and P30 (p = 0.04) but 
normalizes at P60 (Figure 5B). There is no difference in 5252Cryo2010 compared to euploid 
when measuring the M-L length of the telencephalon at P15, P30, or P60 (Figure 5C). 
This contrasts with the 52522019 animals which have no difference in R-C length at any age 
but do show a significantly reduced M-L length at P60 (p = 0.02, Figure 5C). 
Abnormal hind-limb reflex in Ts65Dn males 
During development, infants with DS show delays in motor and reflex development 
and typically display hypotonia (Morris et al., 1982). Likewise, in Ts65Dn mice, abnormal 
hindlimb reflexes appear early on and are present throughout life. These reflexive 
abnormalities are thought to be due to changes in the cerebellum or spinal cord that affect 
muscle tone and motor coordination making it a comparable measurement for motor 
development and control (Aziz et al., 2019). This behavior is scored here on a three-point 
scale, with a score of 0 indicating a normal response of splayed hind limbs, a 1 indicating 
the retraction of 1 hind limb, and a score of 2 indicating both hind limbs are retracted when 
an animal is lifted by the tail. 5252Cryo2010 males have no alteration in their hind limb reflex 
compared to controls at any age (Figure 6A). However, 52522019 mice show an increase in 
the splay score compared to controls at P15 (p = 0.001), P30 (p = 0.02), and P60 (p = 0.04), 
suggesting an altered reflexive response in this cohort throughout adulthood. These results 
suggest that although 5252Cryo2010 mice show gross brain anatomical changes, similar to 




and reflexes. Conversely, 52522019 mice, while smaller in body size, do not have reduced 
brain size but do show impaired motor and reflexive skills.  
Discussion  
 Smaller body and overall brain size are known traits of individuals with Down 
syndrome and early characterizations of Ts65Dn show these to be present in the mice as 
well (Cronk et al., 1988; Richtsmeier et al., 2000; Farkas et al., 1985; Farkas et al., 1985; 
Frostad et al., 1971; Fischer-Brandies, 1988; Bagic & Verzak, 2003; Chakrabarti et al., 
2007; Roper et al., 2006; Aziz et al., 2018; Costa et al., 2010). However, original reports 
of postnatal body and brain size were from the 1924 line of Ts65Dn and have not been 
fully investigated in the 5252 line. Body weight measurements show that 5252Cryo2010 and 
52522019 mice are smaller at P15 and P30 but this is normalized by P60 in both colonies 
(Figure 5A). This contrasts with what was previously seen in the 1924 line of Ts65Dn 
where mice were smaller in body weight throughout the lifespan (Roper et al., 2006) and 
what is known from other cohorts of 5252, which are smaller in body weight from P5 to 
P12 as well as at 4-5 months of age (Aziz et al., 2018; Costa et al., 2010). In addition to 
variants in body weight changes, measurements of the R-C dimension of the brain show a 
shortening in 5252Cryo2010 males until P60 but this phenotype is not present in 52522019 
(Figure 5B). Brachycephaly, or the shortening of the brain length, is known in people with 
Down syndrome and has been characterized in 1924 Ts65Dn as well (Richtsmeier et al., 
2000). Our research here shows that while the early iterations of 5252 (5252Cryo2010) have 




suggesting not all cohorts of 5252 and 1924 animals are identical in their postnatal 
anatomical phenotypes, as previously assumed.  
The discrepancy in findings could be due to various factors, one of these being 
housing facility conditions and diet. Mice, particularly trisomic animals, are especially 
susceptible to the effects of husbandry practices including caging materials, environmental 
enrichment, noise levels, and cage density (Würbel et al., 2001; Van de Weerd et al., 2002). 
The degree of stress imparted onto Ts65Dn dams from these conditions could affect 
maternal caregiving, resulting in litters with more or less impacted phenotypes. 
Additionally, the nutritional composition and contaminants in rodent chow vary between 
facilities, and even between lots. The nutritional content of the chow has known effects on 
mice (Barnard et al., 2009) and differences in the particular nutrient makeup between 
research facilities could account of the differences seen in results. In our studies here, great 
care was taken to reduce the variability due to the environmental conditions, with all 
animals being reared in the same facility under similar conditions. However, small 
variations could influence the development of the mice and resulting neuroanatomical 
phenotypes. 
Variability in gross brain anatomy has also been documented during embryonic 
development in Ts65Dn. Early characterizations of the 1924 line of Ts65Dn found trisomic 
fetuses to have a reduced M-L brain length as well as decreased pallial thickness that does 
not normalize until embryonic day (E) 18.5 (Chakrabarti et al., 2007). However, animals 
from the 1924 cohort studied more recently (19242017) have no changes in anatomical brain 




a progressive change in phenotype severity. The 5252Cryo2010 cohort shows no change to 
the M-L dimension of brain size but transient reductions in R-C length and pallial thickness 
at E14.5 that normalize by E15.5 (Shaw et al., 2020). This contrasts with the most recent 
cohort of Ts65Dn (52522019) that shows a decrease in R-C length at E15.5 but a significant 
increase in pallial thickness at E14.5, contrary to what was seen in 1924 and earlier 5252 
mice (Shaw et al., 2020). These examples, and our results here, illustrate how 5252 mice 
do not always express the same gross anatomical phenotypes as the 1924 line, or even those 
documented in other 5252 cohorts. These detailed differences underscore the importance 
of repeating experiments between lines and across time as phenotypes may change and 
cannot be presumed stable. 
Understanding and modeling these characteristics of the DS brain at all stages of 
development is important as the cognitive deficits in DS are thought to originate from 
delays in neurological development during gestation that impact postnatal brain structure 
and function. Human fetuses with Down syndrome show reduced stem cell proliferation 
(Guidi et al., 2008) that contributes to the smaller brain sizes seen throughout life. 
Likewise, during embryonic development in mouse models of Down syndrome, various 
neural precursor cell types are under-produced and have slower cell division rates, limiting 
the population of precursor cells that can generate neurons (Haydar et al., 2000; Tyler and 
Haydar, 2013; Chakrabarti et al., 2007; Contestabile et al., 2007). As most neurons in the 
brain are produced during gestation, these early perturbations underlie many of the 
postnatal reductions to brain size and volume and contribute to the cognitive deficits in 




syndrome during adulthood, treatments during the prenatal period may be more effective. 
However, if these basic neuroanatomical phenotypes in these animals are subject to change 
over time, the use and effectiveness of this model as a research tool for identifying targets 
for therapy will be diminished. For this reason, having a mouse model that accurately 
represents the prenatal neurological deficits in DS, as well as the resulting postnatal 











   
Figure 5. Gross body and brain measurements across the lifespan in 
different colonies of Ts65Dn. Boxplots show median value ± Q1 & Q3 with 
individual data points. All comparisons are unpaired two-way Student’s t-test 
between trisomic and relative euploid control with a probability level of p < 
0.05 considered statistically significant. A) Body weight of euploids and 
Ts65Dn at P15 (5252
Cryo2010
 n = 7, 9; 5252
2019
 n = 19, 5), P30 (5252
Cryo2010
 n = 
8, 7; 5252
2019
 n = 10, 10), and P60 (5252
Cryo2010
 n = 8, 8; 5252
2019
 n = 5, 5). 
B&C) Rostral-caudal (B) and medial-lateral length (C) measured as shown in 
Figure 2D at P15 (5252
Cryo2010
 n = 7, 9; 5252
2019
 n = 19, 5), P30 (5252
Cryo2010
 
n = 8, 7; 5252
2019
 n = 10, 10), and P60 (5252
Cryo2010
 n = 6, 6; 5252
2019
 n = 5, 
5). D) Representative image of euploid (left) and 5252
Cryo2010
 (right) brains at 






Figure 6. Hindlimb reflex abnormalities in different cohorts of 
Ts65Dn. Bar graphs display mean ± SEM. All comparisons are 
unpaired two-way Student’s t-test between trisomic and relative 
euploid control with a probability level of p < 0.05 considered 
statistically significant. A) Hindlimb reflex measured at P15 
(5252
Cryo2010
 n = 20, 15; 5252
2019
 n = 19, 5), P30 (5252
Cryo2010
 n = 8, 
7; 5252
2019
 n = 10, 10), and P60 (5252
Cryo2010
 n = 12, 12; 5252
2019
 n 





Comparison of hippocampal and cerebellar cell densities across Ts65Dn mice 
Introduction 
 One major feature of Down syndrome, which is present at birth and persists 
throughout life, is the reduced size and cellular density of the hippocampus and cerebellum 
(Crome et al., 1966; Pinter et al., 2001; Winter et al., 2000; Guilhard-Costa et al., 2006; 
Guidi et al., 2008; Guidi et al., 2011; Golden et al., 1994; Kesslak et al., 1994; Aylward et 
al., 1997; Aylward et al., 1999; Teipel et al., 2003; Raz et al., 1995). During fetal 
development there is a decrease in volume and cell number of both the dentate gyrus 
granular layer and hippocampal pyramidal layer (Guidi et al., 2008). The volumetric 
reduction is also present in young children with Down syndrome and seen into adulthood 
(Smigielska-Kuzia et al., 2011; Pinter et al., 2001). Modeling this common aspect of DS 
in mice is difficult as volumetric and density analyses using Ts65Dn mice have generated 
varied results concerning hippocampal architecture. Reports using the 1924 Ts65Dn line 
found decreased neuronal numbers within the dentate gyrus but no change in cell number 
within CA1 or CA3 at 3 months of age (Lorenzi & Reeves, 2006). At 6 months of age in 
the 1924 Ts65Dn line there was a decrease in neuronal density within the dentate gyrus of 
the hippocampus, an increase in density within CA3, but no change in CA1 (Insausti et al., 
1998). Lastly, aged mice (16-17 months) showed no change in neuronal density in the 
dentate gyrus or CA3 but a significant decrease in CA1 (Kurt et al., 2004) suggesting 




 The hippocampus is heavily involved in learning and memory behaviors and 
hippocampal dysfunction may underlie many of the cognitive symptoms in people with 
DS. Long-term memory, especially for visual object association, is negatively affected in 
Down syndrome and this could be due to deficiencies in memory encoding and retrieval 
(Carlesimo et al., 1997; Vicari et al., 2000). The CA1 and CA3 regions are of particular 
interest as they are thought to be critical for spatial learning. Lesion studies have shown 
CA1 and CA3 are involved in the formation of memories about sequencing of spatial 
locations (Hunsaker et al., 2008). Both the 1924 and 5252 line of Ts65Dn have documented 
deficits in hippocampal-dependent learning and memory tasks (Olmos-Serrano et al., 2016; 
Sago et al., 2000; Reeves et al., 1995; Coussons-Read et al., 1996; Escorihuela et al., 1998; 
Martinez-Cue et al., 2002; Costa et al., 2010). Changes to neuronal density in the circuitry 
involved in such behaviors could underlie the impairments seen in mice, as well as in 
people with DS, making the hippocampus of particular interest in the study of Down 
syndrome.   
 Just as with the hippocampus, the cerebella of people with DS are smaller in overall 
volume and cellular density (Pinter et al., 2001; Schmidt-Sidor et al., 1990; Guidi et al., 
2011; Crome et al., 1966; Aylward et al., 1997). During fetal development, the cerebellum 
is smaller in terms of weight and displays hypocellularity in the internal and external 
granular layer, the molecular layer, and the Purkinje cell layer (Guidi et al., 2011). 
Following birth, children with Down syndrome have reduced overall volume of the 
cerebellum with both gray and white matter being smaller (Pinter et al., 2001). As in the 




throughout life in people with Down syndrome (Aylward et al., 1997). The cerebellum is 
implicated in motor control and movement planning/execution and disorganized cerebellar 
structure may affect emotion and cognitive function as well (Schmahmann, 2004; Teipel 
et al., 2004; Strick et al., 2009; Schmahmann, 2010; Buckner, 2013). Nearly all infants 
with Down syndrome display hypotonia and later in life show delayed development of 
motor skills and abnormal gait patterns (Morris et al., 1982; Malak et al., 2015; Palisano 
et al., 2001; Agiovlasitis et al., 2009) which all could be due to altered cerebellar structure 
and function. 
The 1924 line of Ts65Dn shows similar cerebellar-related phenotypes to those seen 
in humans. Trisomic mice from the 1924 strain have reductions to cerebellar volume as 
well as reduced cell density of both granule and Purkinje cells from birth through adulthood 
when compared to euploid controls (Baxter et al., 2000; Olson et al., 2004; Roper et al., 
2006). These findings are consistent among the 1924 line of Ts65Dn but the cerebellar 
phenotypes, as well as the hippocampal measurements, have not been fully evaluated in 
the 5252 line. Confirming phenotypes across cohorts of Ts65Dn is important as 
pharmacological therapies for people with Down syndrome, aimed at improving post-natal 
cognition and development, are often tested using the Ts65Dn model. If target phenotypes 
do not accurately model the human condition and are not stable across time, the Ts65Dn 
model is not an effective platform of drug development for Down syndrome. In this study, 
we evaluate cellular density within the hippocampus and cerebellum from three cohorts of 




hypocellularity phenotypes between the 1924 and 5252 lines as well as within individual 
cohorts of 5252 mice.  
Results 
Histology reports show that humans with Down syndrome have decreased 
hippocampal and cerebellar volumes and cellular densities (Olson et al., 2007; Winter et 
al., 2000; Guilhard-Costa et al., 2006; Guidi et al., 2008; Guidi et al., 2011; Golden et al., 
1994; Kesslak et al., 1994; Aylward et al., 1997; Aylward et al., 1999; Teipel et al., 2003) 
and it has been shown that Ts65Dn mice from the 1924 line recapitulate these phenotypes 
as well, but to varying degrees dependent upon age in the hippocampus (Lorenzi et al., 
2006; Insausti et al., 1998; Kurt et al., 2004; Ayberk et al., 2004; Olson, et al., 2004; Baxter 
et al., 2000, Roper et al., 2006). To determine whether these brain regions exhibit stable 
reductions in size across generations of the 5252 line, we measured the neuronal density in 
CA1 and CA3 of the hippocampus and in Lobule III and IV/V of the cerebellum (Figure 
7) in P60 males of three temporal cohorts of Ts65Dn mice: 5252Cryo2010 (n = 5 euploid, 5 
trisomic (3 litters)), 52522015 (n = 5 euploid, 3 trisomic), and 52522019 (n = 5 euploid, 5 
trisomic). Tissue was stained for neuronal marker NeuN and Z-stack images were collected 
for each of the respective regions. All NeuN+/DAPI+ cells were counted within a 
designated region of interest throughout the depth of the Z-stack image. Density was 
calculated for each image and trisomic values were normalized to euploid controls. Our 
results show that none of the three generations of Ts65Dn exhibit a decrease in cell density 
in CA1 or CA3 of the hippocampus nor in Lobules III or IV/V compared to their euploid 




characterized in the 1924 line Ts65Dn mice are not present in all generations of the 5252 
line of Ts65Dn. 
Discussion 
 The cognitive and motor deficits in Down syndrome have underlying mechanisms 
based on structural alterations to the hippocampus and cerebellum. This phenotype had 
previously been identified in the 1924 line of Ts65Dn (Lorenzi and Reeves, 2006; Insausti 
et al., 1998; Ayberk et al., 2004; Olson et al., 2004; Baxter et al., 2000, Roper et al., 2006). 
To confirm the presence or absence of these characteristics in 5252 Ts65Dn animals, we 
calculated the neuronal density in sub-regions of the hippocampus and cerebellum of three 
cohorts of 5252 (5252Cryo2010, 52522015, and 52522019). There was no difference in density 
of cells in CA1, CA3, nor Lobule III or IV/V of the cerebellum, between trisomic and 
euploid animals at P60. This contrasts with results from the 1924 line that show a varied 
decrease in volume and cell density across the lifespan in trisomic animals (Lorenzi et al., 
2006; Insausti et al., 1998; Kurt et al., 2004; Ayberk et al., 2004; Olson, et al., 2004; Baxter 
et al., 2000 Roper et al., 2006).  
 Findings related to neuronal density may vary across studies due to a number of 
factors, one being experimental design as different methods of density measurement could 
influence outcome. To account for this, our approach normalized the trisomic density 
values to respective euploid controls to better capture differences between the genotypes. 
Additionally, cell density was calculated based on a defined region of interest for each 
image as opposed to a predefined volume to account for differences in total hippocampal 




Discrepancies in results could also be due to the age of the mice being sampled. Our current 
findings in the hippocampus from P60 mice show no change to cell density in CA1 or CA3 
which aligns with Lorenzi et al. (2006) who found no change in these regions at 3 months 
of age. However, our findings differ from those of Insauti et al. (1998) which found no 
change in density of CA1 but an increase in CA3 around 6 months of age. Lastly, 16 month 
old mice studied by Kurt et al. (2004) showed a decrease in cell density in CA1 but no 
change to CA3. It is known that neuronal loss increases and adult neurogenesis decreases 
in the hippocampus with age (Flood & Goleman, 1988; Kempermann et al., 2002) and this 
is true in Ts65Dn as well (Holtzman et al., 1996; Rueda et al., 2005). Therefore, the varied 
results seen in hippocampal cell densities could be a consequence of age-depended changes 
that make direct comparisons across ages implausible. 
Although cell density is not altered in the 5252 line of Ts65Dn, this does not mean 
that the cells present or the circuitry of the hippocampus are functioning properly. The 
hippocampus is necessary for memory formation and integration of incoming information. 
The perforant path sends information to granule cells within the dentate gyrus. The granule 
cells then make synaptic connection with pyramidal cells of CA3. From there, axons 
transmit information to CA1 (Kanel et al., 2012). A small number of cells are involved in 
this circuitry and thus, minor alterations to the system could result in large changes in 
function. In addition to having fewer cells in the hippocampus, Ts65Dn mice have fewer 
synapses in CA1 and CA3, compared to euploid controls, as well as reduced LTP and 
increased LTD capacity, which contributes to the impaired cognitive state of Ts65Dn 




2004). Therefore, altered cell number alone does not dictate the function of the 
hippocampus in Ts65Dn. If learning and memory abilities are reduced in Ts65Dn mice due 
to synaptic plasticity changes, total neuronal numbers may not need to be significantly 
reduced to see behavioral changes. In fact, within the 5252Cryo2010 cohort, we see no changes 
in hippocampal cell density (Figure 7A) although we see noticeable learning and memory 
deficits on MWM performance (Chapter 4) suggesting that the underlying mechanisms of 
cognitive impairment in Ts65Dn are not solely dependent on reduced hippocampal cell 
density.  
 Within the cerebellum, our analysis of P60 5252 mice found no change in the 
density of cells between trisomic mice and euploid controls. This contrasts with initial 
reports of 1924 Ts65Dn animals that measure a decrease in granule cell density consistently 
from P6 to P35 and a significant decrease in both granule and Purkinje cell density in 4-12 
month old mice (Baxter et al., 2000; Roper et al., 2006). The differences in cerebellar 
phenotypes between the 1924 line and the 5252 line of Ts65Dn could be due to the genetic 
background on which the mice are maintained. The 1924 line is generated by backcrossing 
Ts65Dn females to C57BL/6JEi ˣ C3H/HeSnJ (B6EiC3Sn F1 Hybrids) that contain a 
mutation within the Pde6Brd1 gene that results in retinal degeneration. The 5252 line is 
maintained on a congenic B6EiC3Sn background that does not carry the blindness-causing 
mutant allele. It is expected that the two versions of Ts65Dn, 1924 and 5252, are genetically 
identical except for the Pde6brd1 mutation, although this has not been experimentally 
confirmed. Behavioral comparison of these mice show they are similar (Costa et al., 2011), 
however, the 5252 line has never been fully assessed in terms of hippocampal and 
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cerebellar structure and thus, these phenotypes had been presumed of 5252 animals. Our 
results here show that 5252 Ts65Dn mice do not express the same cellular density 
phenotypes previously seen in 1924 mice, perhaps due to variance in genetic backgrounds. 
Therefore, further research should be targeted at understanding the genetic similarity 
between these lines and the role that plays in phenotypic variance.  
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Figures 
Figure 7. Hippocampal and cerebellar cell densities assessed in 5252Cryo2010, 52522015, and 
52522019 males at P60. Boxplots show median value ± Q1 & Q3 with individual data points 
with trisomic values normalized to respective euploid controls. All comparisons are unpaired 
two-way Student’s t-test between trisomic and relative euploid control with a probability level 
of p < 0.05 considered statistically significant. A) Density of NeuN+ cells in the CA1 and 
CA3 regions of the hippocampus of 5252
Cryo2010
 (n = 5, 5) and 5252
2015
 (n = 5, 3) and 5252
2019
 
(n = 5, 5) cohorts normalized to their euploid controls presented as percent of control. B) 
NeuN+ cell density in Lobule III and Lobule IV/V of the cerebellum of 5252
Cryo2010
 (n = 5, 
5), 5252
2015
 (n = 5, 3), and 5252
2019
 (n = 5, 5). C-F) Representative images of NeuN staining in 





Variability in oligodendrocyte maturation and myelination across Ts65Dn cohorts 
Introduction 
 Myelin is a lipid-dense membrane, made of oligodendrocytes that extend and wrap 
their processes around axons, providing an insulating sheath that increases the speed of 
neural communication. Axons are wrapped in a pattern of densely myelinated regions, or 
internodes, and non-myelinated segments, called nodes of Ranvier. The assembly of 
myelin in this manner is important for insulating the electrical signal through the axon by 
providing high membrane resistance and low capacitance, and concentrating sodium 
channels at nodes which allows for fast saltatory conduction of action potentials (Mitew et 
al., 2014; Seidl, 2014; Freeman et al., 2016). This insulation is critical in processes like 
long-term potentiation and depression as well as in formation of circuit wiring (Fields, 
2005; Almeida and Lyons, 2017). Thus, alterations during the process of myelin formation 
can have significant impacts on neuronal communication speed and axon survival, 
resulting in impaired cognitive abilities, as there are in Down syndrome.  
 The generation of myelin begins in the third trimester and continues until early 
adulthood in humans (Jakovcevski et al., 2009). Studies have shown that people with Down 
syndrome have alterations to the formation of myelin that first appear as early as 37 weeks 
gestation and are present throughout the lifespan. Fetuses with DS have a reduced amount 
of myelinated fibers and delayed myelin formation following birth (Wisniewski and 
Schmidt-Sidor, 1989; Wisniewski, 1990; Ábrahám et al., 2012).  In adolescents and adults, 




temporal lobes, hippocampus, and corpus callosum (Wisniewski and Schmidt-Sidor, 1989; 
Dambaska and Laure-Kaminonwska, 1990; Ábrahám et al., 2010; Olmos-Serrano et al., 
2016a). Additionally, reduced levels of myelin-related proteins, such as myelin basic 
protein (MBP), myelin associated glycoprotein (MAG), and 2’3’-cyclic nucleotide-3’-
phosphodiesterase (CNPase) have been reported in the brains of people with Down 
syndrome (Banik et al., 1975; Palminiello et al., 2008; Vloklinský et al., 2001; Palo and 
Savolainen, 1973; Olmos-Serrano et al., 2016a). These findings suggest that the process of 
myelination is impaired in DS, and knowing that proper myelination is critical to neural 
communication, these perturbations could underlie the cognitive deficits that are 
widespread in the syndrome.  
 Similar findings have been seen in the Ts65Dn mouse model of Down syndrome. 
Western blot analysis of the cingulate white matter in these mice showed reduced MAG 
and MBP protein levels and fewer myelinated fibers into the superficial layers of the cortex 
(Olmos-Serrano et al., 2016a). Electron micrographs of the corpus callosum in Ts65Dn 
animals show that, although the total number of myelinated axons are not different between 
trisomic and euploid animals, trisomic animals have a significantly increased g-ratio 
(Olmos-Serrano et al., 2016a). The g-ratio quantifies the thickness of myelin compared to 
axon bore diameter, for which a larger value indicates thinner myelin per axon. The 
increased g-ratio has functional consequences; action potential conduction velocity, 
measured using compound action potential recordings, was significantly slowed in the 
Ts65Dn animals (Olmos-Serrano et al., 2016a) suggesting that the reduced myelination 




Myelin in the central nervous system is made from the extended processes of 
oligodendrocytes that contact and wrap around axons. In order for oligodendrocytes to 
begin myelinating axons, they must first undergo a complicated and tightly regulated 
maturation process of molecular and morphological changes. During prenatal 
development, neural precursors begin to differentiate into oligodendrocyte precursor cells 
(OPCs) and migrate to what will be the major white matter tracts in the brain (Tekki-
Kessaris et al., 2001; Chapman et al., 2013; Kessaris et al., 2006; Goldman and Kuypers, 
2015). It is not until postnatal periods in mice that these OPCs begin to differentiate, 
eventually maturing into myelinating oligodendrocytes. Up and down-regulation of 
specific genes occurs in a temporally restricted manner to guide the cell-autonomous 
maturation of OPCs (Traiffort et al., 2016). The maturation of the oligodendrocyte lineage 
is in part cell-intrinsic but their environment also greatly impacts the success of this 
maturation and the speed at which it occurs. Reduced levels of key growth factors or 
dysregulation of gene expression can significantly impair an oligodendrocyte’s ability to 
properly differentiate and myelinate (Baumann and Pham-Dinh, 2001; Marinelli et al., 
2016; Temple and Raff, 1986; Waly et al., 2014). Alterations at any point along this process 
can result in changed numbers of or improperly functioning oligodendrocytes, which can 
impact the quality of myelin.  
Transcriptomic studies have shown that trisomy 21 affects transcriptional networks 
associated with the oligodendrocyte lineage that may negatively impact the ability of 
trisomic cells to properly mature and myelinate axons, impairing action potential 




Olmos-Serrano et al. (2016a) utilized genome-wide transcriptome profiling of post-mortem 
brains from individuals with Down syndrome to reveal alterations in gene expression 
across the genome. Further weighted-gene co-expression network analysis (WGCNA) 
identified modules of co-expressed genes that were dysregulated in DS samples and gene 
ontology (GO) enrichment analysis detected modules with biological processes that were 
not previously associated with Down syndrome (Olmos-Serrano et al., 2016a). One module 
that was significantly down-regulated in DS samples was enriched for GO terms related to 
axon ensheathment and action potential regulation. The genes within this module were 
most highly expressed in the oligodendrocyte lineage (Olmos-Serrano et al., 2016a), 
suggesting gene-expression dysregulation of oligodendrocyte-specific genes may be 
impacting myelin formation and function.  
Some of the genes belonging to this module include MAG, MOG, CNP, SOX10, 
and MYRF (Olmos-Serrano et al., 2016a). These genes are all primarily expressed by 
oligodendrocytes and are crucial in the regulation of oligodendrocyte development and 
myelin production. SOX10 is expressed by the oligodendrocyte lineage and essential for 
the differentiation and maturation of OPCs to a mature state (Stolt et al., 2002) in part by 
regulating the expression of MYRF (Hornig et al., 2013), a transcription factor that 
promotes the expression of MAG, MOG, MBP, and CNP and is required for myelination 
(Emery et al., 2009; Aprato et al., 2019; Bujalka et al., 2013). Removing the expression of 
MYRF significantly reduced the expression of these myelin-related genes (Koenning et al., 
2012). MAG proteins are necessary for the formation of myelin sheaths as they are located 




well as signaling to oligodendrocytes about which axons require myelination (Li et al., 
1994). Reduced expression of MAG is associated with hypomyelination (Meyer-Franke 
and Barres, 1994). CNPase is located in the cytoplasm of non-compacted oligodendrocytes 
that are ensheathing axons (Trapp et al., 1988) and overexpression of CNP disrupts 
oligodendrocyte development and causes abnormal myelination (Gravel et al., 1996). 
These genes are part of an interconnected regulatory network that guides the process of 
oligodendrocyte maturation and myelin formation and abnormal expression of any one can 
impact myelination. As the expression of these genes is down-regulated in DS, this could 
contribute to the reduced myelination seen in many people with Down syndrome.  
To further uncover the underlying molecular mechanisms driving altered 
myelination in Down syndrome, Olmos-Serrano et al. (2016a) measured the maturation of 
oligodendrocytes in the 52522014 line of Ts65Dn. They found trisomic mice had 
significantly few mature oligodendrocytes compared to euploid controls, within the corpus 
callosum at P15 and P60. Additionally, they found fewer trisomic OPCs reach a mature 
state in vitro, suggesting there is an intrinsic inability of trisomic OPCs to properly mature, 
producing fewer oligodendrocytes that are then able to myelinate (Olmos-Serrano et al., 
2016a). Each oligodendrocyte can generate 20-60 myelinating processes that will ensheath 
multiple axons (Nave and Werner, 2014; Simons and Nave, 2015). This means that even a 
small reduction in the number of mature oligodendrocytes, as seen in the 52522014 Ts65Dn 
animals, can affect the neurotransmission of a large number of neurons.  
This novel avenue of research provides evidence for a unique target for 




dysmyelination phenotype is present in both people with Down syndrome as well as in the 
Ts65Dn line, making these mice a useful platform to continue investigating myelination 
disruption in the syndrome. However, as we have seen a loss or change in severity of other 
phenotypes in the Ts65Dn line, validation of the white matter phenotype is necessary. To 
evaluate the permanence and stability of the previously identified changes in the 52522014 
line of Ts65Dn related to white matter (Olmos-Serrano et al., 2016a), we investigated the 
maturation of oligodendrocyte populations in the 5252Cryo2010, 52522015, and 52522019 
cohorts of Ts65Dn.  
Results 
Oligodendrocyte maturation across cohorts 
 Previous reports have shown trisomic mice have few mature oligodendrocytes 
compared to euploids (Olmos-Serrano et al., 2016a). Specifically, Olmos-Serrano et al. 
(2016a) showed 52522014 mice had significantly fewer mature oligodendrocytes in the 
corpus callosum at P15 and P60. To determine the reliability of this white matter phenotype 
within Ts65Dn mice, we have assessed the oligodendrocyte populations within the corpus 
callosum from three different generations of Ts65Dn at multiple ages. The 5252Cryo2010 
colony showed no change in proportion of mature oligodendrocytes at P15 (n = 5, 4), P21 
(n =5, 5), P30 (n = 4, 5), or P60 (n = 6, 6) compared to euploid controls (Figure 8A). 
Similarly, the 52522015 colony showed no changes to the percentage of mature 
oligodendrocytes at P15 (n = 7, 4), P21 (n = 9, 7), or P60 (n = 3, 3) (Figure 8B). However, 




P30 (n = 5, 5; p = 0.05) and P60 (n = 5, 5; p = 0.05), similar to the previous findings, 
illustrating how this phenotype can vary from generation to generation of Ts65Dn mice.  
Myelin-related gene expression 
To determine if changes in oligodendrocyte maturation impact myelin-related gene 
expression, we measured the expression levels of MAG and MBP in the corpus callosum 
and cortex of 5252Cryo2010 and 52522019 mice with RT-qPCR (Figure 9A). Prior work in 
Ts65Dn mice have shown significant decreases in myelin-related proteins in Ts65Dn mice 
(Olmos-Serrano et al., 2016a), however, analysis of these other cohorts (5252Cryo2010 and 
52522019) shows no change in the gene expression levels of MAG or MBP in the cortex in 
either generation of Ts65Dn. However, we do see a significant reduction in MBP 
expression in the corpus callosum of trisomic 52522019 mice compared to euploid controls 
(n = 5, 5; p = 0.047).  
In-vitro culture of trisomic OPCs 
 Oligodendrocytes must undergo a regulated maturation process in order to 
myelinate axons and this differentiation and development can be impacted by the genetic 
composition of the OPCs themselves as well as the surrounding environment. Olmos-
Serrano et al. (2016a) isolated OPCs from 52522014 pups and found trisomic OPCs had an 
intrinsic deficit in their ability to differentiate and develop, producing fewer mature 
oligodendrocytes in vitro. This would suggest that the reduced population of mature 
oligodendrocyte in vivo stems from an inability of trisomic OPCs to mature properly. To 
confirm this finding in another cohort of Ts65Dn animals, OPCs were cultured from 




of mature oligodendrocytes between euploid and trisomic cultures (Figure 9B). Taken 
together, these studies show how variable a major phenotype can be across generations of 
the Ts65Dn mice, making it difficult for researchers to compare studies across laboratories 
and across time. 
Discussion 
  Abnormal white matter formation is a known characteristic of Down syndrome 
(Wisniewski and Schmidt-Sidor, 1989; Wisniewski, 1990; Ábrahám et al., 2012; 
Dambaska and Laure-Kaminonwska, 1990; Olmos-Serrano et al., 2016a; Banik et al., 
1975; Palminiello et al., 2008; Vloklinský et al., 2001; Palo and Savolainen, 1973) and 
these phenotypes are present in Ts65Dn mice from the 52522014 cohort (Olmos-Serrano et 
al., 2016a). To determine the stability of this phenotype in the 5252 line of Ts65Dn, we 
measured the population of mature oligodendrocytes within the corpus callosum at various 
ages in 5252Cryo2010, 52522015, and 52522019 mice. We found no change in the 5252Cryo2010 
or 52522015 cohorts but there was a significant reduction in mature oligodendrocytes in the 
trisomic mice of the 52522019 cohort, which aligns with original findings from Olmos-
Serrano et al. (2016a).  
 The variability in findings across 5252 cohorts, similar to the phenotypes assessed 
in Chapter 1, may be due to colony maintenance and breeding strategies that can 
inadvertently generate sub-colonies of Ts65Dn that differ in phenotype presence and 
severity. Ts65Dn colonies are maintained by crossing a trisomic female with an F1 Hybrid 
male (B6EiC3Sn). Long-term maintenance of Ts65Dn is difficult as some trisomic dams 




2005). However, some Ts65Dn females give birth and care for offspring without difficulty. 
Thus, females that have high success rates with breeding and litter care inevitably represent 
a larger proportion of any maintenance colony. Maternal care can mediate behavioral 
variations in offspring (Fairbanks and McGuire, 1988; Meaney, 2001) suggesting the 
importance of maternal-offspring interactions. Additionally, small differences in genetic 
factors between wildtype strains of mice can greatly impact maternal responsivity 
(Champagne et al., 2007). If genetic changes associated with increased breeding fitness in 
Ts65Dn dams are correlated with improved phenotypes of the offspring, then this could 
lead to a predominance of litters with altered or reduced phenotypic severity. If selective 
breeding occurs over generations, “mini-colonies” of Ts65Dn could emerge in individual 
laboratories and these sub-colonies could exhibit a particular set of phenotypes that differs 
from other labs.  
 This may explain why shifts in phenotypes, such as we observed with the 
oligodendrocyte maturation phenotype, are detected when new breeding females are 
imported from Jackson Laboratories, which may cause a disruption in the cycle of selective 
breeding. For example, when measuring the oligodendrocyte maturation phenotype, 
original data from Olmos-Serrano et al. (2016) identified a decrease in the percentage of 
mature oligodendrocytes in Ts65Dn animals bred in-house between the years 2012-2014. 
However, when we measured the same phenotype with the same methodology but from 
two separate sets of imported breeding dams (5252Cryo2010 and 52522015) these other cohorts 
did not exhibit alterations in the population of mature oligodendrocytes. Moreover, a recent 




percentage of mature oligodendrocytes. If selective breeding practices within an individual 
lab are unintentionally influencing the phenotypic composition of that colony, it is likely 
that their animals now differ dramatically from other laboratory’s colonies or from the 
commercial colony at Jackson Laboratories. Understanding this as a possibility, 
researchers must exercise caution when breeding Ts65Dn animals and consider the effects 
of selective breeding on their observed phenotypes.  
 Although Ts65Dn has produced variable findings related to oligodendrocyte 
development and myelination in DS, studies with post-mortem human tissue have shown 
reduced levels of myelin-related proteins (Banik et al., 1975; Palminiello et al., 2008; 
Vloklinský et al., 2001; Palo and Savolainen, 1973; Olmos-Serrano et al., 2016a). 
Additionally, transcriptomic analyses from human samples have revealed perturbations to 
the genetic networks involved in myelination and oligodendrocyte development (Olmos-
Serrano et al., 2016a) further suggesting that altered myelination is a clinical feature 
present in many people with Down syndrome. Although it is difficult to mimic all aspects 
of a human condition in mice, models should strive to recapitulate the most prevalent 
characteristics. Mouse models are required for experimental manipulation that will allow 
for further assessment of underlying mechanisms contributing to DS phenotypes and test 
potential treatment options. Dysmyelination could be a major contributor to the cognitive 
deficits in Down syndrome making it a potential target for therapeutic opportunities. In 
fact, studies in mice have found compounds that promote OPC maturation and increase the 
levels of myelin (Mei et al., 2014; Li et al., 2015) have positive effects on action potential 
conduction velocity and learning and memory behaviors (Cree et al., 2018; Li et al., 2015). 
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Additionally, these compounds have shown to increase OPC maturation in human cells 
(Najm et al., 2015) and improve clinical outcomes such as visually evoked potential 
latencies in multiple sclerosis patients (Green et al., 2017) suggesting that targeting OPC 
differentiation may be a viable avenue for treatment in cases of disrupted myelination. In 
the case of Down syndrome, increasing levels of myelination with such treatments could 
significantly improve cognitive abilities and increase the quality of life for individuals. 
However, without a mouse model that exhibits this common feature of Down syndrome, 
development of treatments and testing the effects of these pharmacological agents is 
difficult. Thus, it is of great importance that studies utilizing Ts65Dn, and other models of 
DS, ensure their cohort of animals demonstrates disease-relevant phenotypes and practice 
transparency in order to better advance Down syndrome research.  
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Figures 
Figure 8. Ts65Dn colonies show varied changes 
in oligodendrocyte maturation. Boxplots show 
median value ± Q1 & Q3 with individual data 
points. All comparisons are unpaired two-way 
Student’s t-test between trisomic and relative 
euploid control with a probability level of p < 0.05 
considered statistically significant. A) Percentage 
of mature oligodendrocytes (CC1+/Olig2+ cells) 
within the corpus callosum at P15 (n = 5, 4), P21 (n 
= 5, 5), P30 (n = 4, 5), and P60 (n = 6, 6) of 
5252
Cryo2010
 males. B) Percentage of CC1+/Olig2+ 
cells counted within the corpus callosum of euploid 
and 5252
2015
 male mice at P15 (n = 7, 4), P21 (n = 
9, 7), and P60 (n = 3, 3), with no significant 
differences between genotypes. C) Percentage of 
CC1+/Olig2+ mature OLs in the corpus callosum of 
5252
2019
 males at P15 (n = 5, 5,), P30 (n = 5, 5), and 
P60 (n = 5, 5). D&E) Representative images of the 
corpus callosum stained with CC1, Ng2, and Olig2 




Figure 9. Myelin-related gene expression and cell intrinsic properties of OPCs. Bar 
graphs show mean ± SEM. All comparisons are unpaired two-way Student’s t-test 
between trisomic and relative euploid control with a probability level of p < 0.05 
considered statistically significant. A) RT-qPCR gene expression analysis for myelin-
related genes in the corpus callosum and cortex of 5252
Cryo2010
 (n = 5, 5) and 5252
2019
 
(n = 5, 5) P30 males normalized to expression of respective gen in euploid controls 
shows a significant reduction of MBP expression in the corpus callosum of 5252
2019
 
mice (p = 0.047) only. B) Graph compares mature O1+ OLsin cultures from 
5252
Cryo2010 
and euploid littermate controls (n = 4, 2) with no statistical difference 
between genotypes. C&D) Representative images of control (C) and 5252
Cryo2010
 (D) 
OPCs isolated from P0 pups and cultured in vitro and differentiated for 72 hours. 











Developmental and behavioral characterization of 5252Cryo2010 mice  
Introduction 
 Motor and cognitive deficits arise early and are present throughout the lifespan for 
people with Down syndrome. At birth and during the first years of life, infants with DS 
show delays in the acquisition of developmental milestones, such as crawling and walking 
(Malak et al., 2015; Connolly et al., 1993; Haley, 1989; Palisano et al., 2001; Hartley, 
1986; Matson et al., 2010; Horovitz and Matson, 2011; Cardoso et al., 2015). Infants with 
DS are reported to stand upright and begin walking over a year later than typically 
developing children (Malak et al., 2015; Ulrich et al., 2001). These developmental 
impairments impact motor strength and function which in turn may cause slowed 
development of cognitive abilities, as weakened motor function limits the ability to explore 
and learn about the environment.  
 The most penetrant feature of Down syndrome is intellectual disability which can 
manifest as a decline in IQ, reduced language capabilities, and changes to hippocampal-
based explicit and spatial memory (Wishart, 1993; Gibson et al., 1988; Ohr and Fagen, 
1994; Pennington et al., 2003; Vicari, 2004; Vicari et al., 2013). In particular, people with 
Down syndrome exhibit weaker verbal short-term memory skills and allocentric spatial 
learning relative to visuo-spatial short-term memory (Lavenex et al., 2015; Marcell and 
Armstrong, 1982; Jarrold et al., 2006). Additionally, these individuals demonstrate 
changes to long-term memory capabilities (Carlesimo and Vicari, 1997; Jarrold et al. 2007; 




 The Ts65Dn mouse model of Down syndrome has similar early-life deficits 
followed by continued cognitive impairments in adulthood. Developmental milestones 
measure the acquisition of gross motor and reflexive skills during early postnatal life in 
mice that parallel the development of early motor and cognitive function in human infants. 
Ts65Dn are significantly delayed in the acquisition of a number of developmental 
milestones including surface righting, negative geotaxis, cliff aversion, rooting, air 
righting, and the auditory startle reflex (Holtzman et al., 1996; Toso et al., 2008; Olmos-
Serrano et al., 2016b; Aziz et al., 2018). Adult learning and memory is also impaired in 
Ts65Dn mice. When tested on the Morris water maze (MWM), trisomic mice take longer 
to locate the hidden platform compared to euploid mice (Reeves et al., 1995; Costa et al., 
2010) and fail to learn the location of the platform during a reversal phase (Stasko and 
Costa, 2004; Sago et al., 2000; Olmos-Serrano et al., 2016b) demonstrating impaired 
spatial learning and cognitive flexibility.  
 Although learning and memory changes have been documented in Ts65Dn mice, 
the details of the findings have not been consistently reproduced over time. Initial 
behavioral characterization of the 1924 line of Ts65Dn found severe impairments in MWM 
performance with trisomic mice showing no learning improvement over trial days during 
the hidden platform phase and increases in latency throughout the duration of the task 
compared to euploid controls (Reeves et al., 1995; Holtzman et al., 1996; Sago et al., 2000; 
Stasko and Costa, 2004). With the development of the 5252 line of Ts65Dn, direct 
comparisons were done to evaluate the cognitive deficits of 5252 mice compared to the 




trisomic mice and the 5252 trisomic mice. Additionally, results from the hidden platform 
phase showed trisomic mice from both strains had increased latencies on average compared 
to euploid controls (Costa et al., 2010). However, the learning and memory impairments 
were not as robust as previously reported; only two of nine trial days were statistically 
different between trisomic mice and controls (Costa et al., 2010) compared to earlier 
accounts with 1924 mice showing increased latencies across all trial days (Reeves et al., 
1995). Similar results were found when studying the 52522014 cohort. Olmos-Serrano et al. 
(2016b) reported that from the fifth day of training on, 2 month old Ts65Dn mice could 
find the hidden platform, just as euploid controls, with no differences in latency, suggesting 
that the trisomic animals exhibited limited learning and memory deficits.  
The published literature provides instances of variable results regarding early life 
development and learning and memory capabilities within the Ts65Dn line. Ts65Dn is 
often the model of choice used to gather pre-clinical evidence for treatment of the cognitive 
impairments in Down syndrome. A majority of these therapies do not progress pass pre-
clinical phases or result in failed clinical trials (Gardiner, 2015, Herault et al., 2017). 
Although intellectual disability is the most common feature of Down syndrome there are 
still no therapies available. The current state of Down syndrome clinical trial research 
warrants a critical evaluation of how effective Ts65Dn is at recapitulating the human 
features of Down syndrome in a manner that translates to treatments. To evaluate the 
behavioral phenotypes of these mice and compare with results across time, we measured 
developmental milestone acquisition and performance on the Morris water maze in the 





Variability in time to acquire developmental milestones 
Prior assessment of these skills in 52522014 animals showed that trisomic Ts65Dn 
mice were delayed in the acquisition of surface righting, negative geotaxis, cliff aversion, 
rooting, air righting, and the auditory startle reflex (Olmos-Serrano et al., 2016b; Aziz et 
al., 2018). In the current study of the 5252Cryo2010 line, male trisomic mice (n = 15) were 
significantly delayed in the development of the ear twitch reflex (p = 0.04), open field 
navigation (p = 0.02), time to eye opening (p = 0.004), negative geotaxis (p < 0.001), and 
surface righting reflex (p = 0.02), when compared to male euploid controls (n = 20) 
(Figures 10&11). Female trisomic 5252Cryo2010 mice (n = 12) were impaired in 
development of cliff aversion (p = 0.003) and open field (p = 0.05) when compared to 
euploid females (n = 20) (Figures 10&12). Although males and females differed in the 
development of various tasks compared to their relative controls, both trisomic males and 
females had significantly greater cumulative developmental milestone (DM) scores than 
euploid controls (Figures 11K&12K, males n = 20, 15, p = 0.001; females n = 20, 12, p = 
0.004) suggesting that both sexes were slower to reach milestones than euploids.  
Results from developmental milestone testing also demonstrates the large degree 
of variance present within both male and female 5252Cryo2010 mice. Table 1 displays the 
calculated variance for males and females of both genotypes for all ten developmental 
milestone tasks. The increased variance within trisomic mice for many tasks suggests that 




same cohort. This would make it difficult to draw comparisons across animals, and even 
more so, across generations of the colony. 
Prior studies evaluating developmental milestone acquisition in 52522014 Ts65Dn 
found that trisomic mice were delayed in surface righting, negative geotaxis, cliff aversion, 
rooting, air righting, and auditory startle (Olmos-Serrano et al., 2016b; Aziz et al., 2018). 
However, the set of behaviors most affected in the present study differs from those 
significantly impacted in previous research. Figure 10K compares the observed delays in 
milestone acquisition between Ts65Dn mice from the 52522014 cohort (Olmos-Serrano et 
al., 2016b; Aziz et al., 2018) versus 5252Cryo2010 mice. Of the ten tasks assessed, only three 
(forelimb grasp, negative geotaxis, and surface righting) show repeatable results between 
studies. These animals were tested and studied in the same laboratory and by the same 
methodology to avoid any confounding variables. The discrepancies in results may be due 
to differences between generations of the Ts65Dn colonies and the inherent variability they 
carry. Our results from studying the acquisition of milestones in 5252Cryo2010 mice show 
that several behaviors are significantly impacted in terms of their developmental timelines 
compared to euploid animals but importantly, trisomic animals are a highly variable 
population, posing difficulty when studying a common phenotype across time and 
generations. 
Impaired learning during Morris water maze 
The Morris water maze task is used to measure an animal’s ability to learn and 
remember spatial navigation cues and has been a long-standing assay to study 




52522014 cohort learned the location of the hidden platform in an extended, 12 day version 
of the task, however, they showed an inability to re-learn the platform location during the 
reversal phase (Olmos-Serrano et al., 2016b), suggesting a loss of cognitive flexibility 
similar to that found in individuals with Down syndrome. To determine the consistency of 
this phenotype, we conducted the extended Morris water maze task with 5252Cryo2010 mice 
to compare performance with the 52522014 Ts65Dn mice previously evaluated. In both 
studies, a cued learning phase was used to acclimate the mice and ensure both genotypes 
were able to learn how to swim to a visible platform. Both the euploid (n = 24) and 
5252Cryo2010 (n = 24) mice successfully learned how to complete the task, as indicated by a 
reduction in the latency to reach the visible platform over the course of the four-day cued 
phase (Figure 13A). 
Following the fourth day of the cued phase, both genotypes moved on to the hidden 
acquisition phase to test their ability to learn the location of a hidden platform using spatial 
cues. Both genotypes decreased the latency to reach the hidden platform over the twelve 
consecutive days (F11, 506 = 4.396, p < 0.0001, n = 24, 24) indicating improved learning and 
memory of the platform location. Genotype significantly impacted the time to reach the 
platform (F1, 46 = 11.28, p = 0.0016, n = 24, 24). 5252Cryo2010 mice performed similarly to 
euploid controls during the early learning phase of the hidden acquisition (Days 1-6) but 
took significantly longer to reach the platform in the later phase (Days 7-12) (Figure 13A, 
p < 0.05 Sidak multiple comparisons post hoc test) suggesting 5252Cryo2010 mice were not 
able to learn the location of the hidden platform as well as euploid controls. Additionally, 




hidden acquisition training (Figure 13D, F1, 46 = 0.006, p = 0.936, n = 24, 24) but trisomic 
mice did have greater total distances traveled compared to euploids (Figure 13E, F1, 46 = 
9.557, p = 0.003, n = 24, 24). 
To quantify hidden acquisition learning, a probe trial was given after the last hidden 
phase training day. During the probe trial, the platform was removed, and mice swam for 
60 seconds while time spent per quadrant was recorded. 5252Cryo2010 mice spent 
significantly less time in the target quadrant compared to euploid controls (Figure 13C, p 
= 0.004) and significantly more time in the release quadrant compared to the target (not 
shown, p = 0.005). This suggests that the 5252Cryo2010 Ts65Dn mice did not effectively learn 
the task during the hidden acquisition phase, as was previously reported for other Ts65Dn 
cohorts (Olmos-Serrano et al., 2016b).  
The Down syndrome field has traditionally focused on studying male Ts65Dn but 
our results indicate that fully studying both sexes may provide more comprehensive 
insights into the effects of trisomy 21. In this study, we tested both male and female 
5252Cryo2010 mice and saw no significant difference by sex in performance on the Morris 
water maze for trisomic animals (Figure 13B, F1, 22 = 1.11, p > 0.999, n = 12, 12) nor 
between euploid males and females (F1, 22 = 0.802, p = 0.380, n = 12, 12, data not shown). 
Our data suggest that in terms of learning and memory, male and female Ts65Dn may not 
have a strong sex-dependent difference and therefore both sexes should be studied in future 
research to further evaluate differences between trisomic males and females. 




Longitudinal studies provide insight into how trisomy can impact an animal 
throughout the life span.  Since the animals studied for developmental milestones were the 
same as those tested in the Morris water maze, we determined whether developmental 
milestones measured were predictive of adult performance on the Morris water maze. We 
calculated a composite DM score for each animal representing their overall developmental 
rate on all ten of the developmental milestones. This allowed for direct comparison across 
behaviors regardless of their average age of acquisition. DM scores for both males and 
females were not strongly correlated with time spent in the target quadrant during the 
hidden probe trial (r22 = -0.32, p = 0.127; r22 = -0.2, p = 0.349, respectively) (Figure 14) 
suggesting that a higher cumulative DM score, or more delayed milestone acquisition, does 
not predict impaired learning in the Morris water maze task in adulthood.  
Discussion 
 Learning and memory difficulties are common among people with Down 
syndrome. Intellectual disability in DS begins early in life, seen as delayed development 
of motor and sensory milestones, and persists into adulthood (Malak et al., 2015; Connolly 
et al., 1993; Haley, 1989; Palisano et al., 2001; Hartley, 1986; Matson et al., 2010; 
Horovitz and Matson, 2011; Cardoso et al., 2015). These deficits are thought to be due to 
structural and functional changes in the brain, specifically to the hippocampus and 
cerebellum (Raz et al., 1995; Pinter et al., 2001). The cerebellar hypoplasia in Down 
syndrome can result in hypotonia, gait instability, and impaired balance and motor 
coordination (Singer et al., 2010). Reduced cellular density of the hippocampal formation 




2003). In addition, changes in myelination can impact coordination and cognitive function 
and it is known that the brains of people with Down syndrome have reduced levels of 
myelin throughout the brain (Wisniewski and Schmidt-Sidor, 1989; Dambaska and Laure-
Kaminonwska, 1990; Ábrahám et al., 2010; Olmos-Serrano et al., 2016a). These three 
perturbations combined, play a role in the early life developmental delays and later 
cognitive deficits in people with Down syndrome.   
 The 5252Cryo2010 cohort of the Ts65Dn line studied here exhibits similar 
developmental and cognitive changes to those seen in people with Down syndrome. These 
mice are delayed in the acquisition of numerous developmental milestones (Figure 10) and 
demonstrate impaired learning and memory performance on the Morris water maze 
(Figure 13). While trisomic mice do display behavioral changes that mimic what we see 
in people with DS, the 5252Cryo2010 cohort does not show abnormalities in the associated 
brain regions.  These mice do not have reduced cellular density in the cerebellum (Chapter 
2), which is thought to contribute to motor function and underlie the delayed acquisition of 
developmental milestones. Likewise, reduced volume and hypo-cellularity of the 
hippocampus is correlated with cognitive deficits of learning and memory however, 
trisomic 5252Cryo2010 mice have no change in the density of cells in the hippocampus 
(Chapter 2), despite showing impaired performance on the Morris water maze. 
Additionally, the trisomic 5252Cryo2010 mice show no changes in oligodendrocyte 
maturation or myelination (Chapter 3) that could also contribute to motor and cognitive 
deficits described. The uncoupling of the cellular and behavioral phenotypes in 5252Cryo2010 




electrophysiological properties, which influence the early life development and later 
learning and memory in Down syndrome.  
 While the 5252Cryo2010 cohort of Ts65Dn does display behavioral deficits, the 
present results underscore the phenotypic variability seen within the Ts65Dn line across 
time. The earliest reports of behavioral changes in Ts65Dn found severe learning and 
memory impairments on the Morris water maze in the 1924 line (Reeves et al., 1995) 
however, comparable studies done with the 1924 line years following the original reports 
found more mild deficits on the Morris water maze (Stasko and Costa, 2004). Additionally, 
the initial Morris water maze studies characterizing the 5252 line in comparison to the 1924 
strain found there to be no difference between the two lines but also showed less severe 
impairment when compared to the euploid controls (Costa et al., 2010). Lastly, trisomic 
animals from the 52522014 cohort show no significant behavioral differences during the 
hidden phase of the Morris water maze task (Olmos-Serrano et al., 2016b) suggesting this 
cohort did not have comparable learning and memory deficits like those of earlier cohorts. 
This time course of behavioral changes highlights the possibility of phenotypic drift in the 
Ts65Dn line in which the earliest iterations of the line had severe cognitive deficits when 
measured on the MWM while more recent cohorts (52522014 from Olmos-Serrano et al., 
2016b) show no differences in learning and memory compared to euploids.   
 Additional factors may explain the discrepancies in Morris water maze 
performance across cohorts. Ts65Dn mice are known to be highly sensitive to the 
environment and performance on behavioral tasks can be influenced by aspects such as the 




apparatus, and even the order in which tasks are administered (Stasko and Costa, 2004). 
These features may vary across laboratories and between experiments, thus altering the 
behavioral output of the animals. Our experimental design sought to control for these 
differences, allowing for an accurate comparison to previous literature, but subtle 
differences may be present that impact results. In addition to animal handling, variations 
in husbandry practices and facilities may contribute to phenotypic differences. Variables 
in animal housing conditions, such as cage materials and bedding, provision of enrichment 
materials, and number of animals per cage are all known to impact rodent behavior (Würbel 
et al., 2001; Van de Weerd et al., 2002). The specific nutrient content of the rodent chow 
provided may also impact the behavioral output of the mice (Barnard et al., 2009). Lastly, 
the level of facility cleanliness and microorganisms or mouse pathogens present can 
influence rodent behavior as well (Burberry et al., 2020). If these variables differ between 
research facilities, the results obtained could be dramatically different between reports and 
explain the variation in results related to learning and memory deficits in Ts65Dn.  
 Overall, our behavioral assessment of the 5252Cryo2010 cohort of Ts65Dn shows 
trisomic mice are slower to develop motor and reflexive skills compared to euploid 
controls. Additionally, trisomic mice demonstrate impaired learning and memory 
capabilities on the MWM. However, there is no relationship between the rate of milestone 
acquisition and MWM performance. Our findings related to MWM learning show impaired 
cognitive abilities in trisomic mice that are more pronounced than those reported on in 
52522014 mice (Olmos-Serrano et al., 2016b) but not as severe as the initial reports with 




differences or could highlight a gradual lessening of phenotypic severity in the Ts65Dn 
line. The differences in behavioral phenotypes between lines and cohorts of Ts65Dn could 
be impacting the advancement of therapeutic studies. With Ts65Dn being the most 
frequently used model for therapeutic discover in DS, loss of phenotypes across time will 
impact the ability of Ts65Dn to predict therapeutic efficacy during the pre-clinical phase. 
The studies presented here draw attention to the need to validate phenotypes in the Ts65Dn 








Figure 10. Developmental milestones measured as average age of acquisition. Boxplots 
show median value ± Q1 & Q3 with individual data points. All comparisons are unpaired 
two-way Student’s t-test between trisomic animals and same-sex euploid control with a 
probability level of p < 0.05 considered statistically significant. A-J) Box plots of 
developmental milestone tasks for euploid males (n = 20), trisomic males (n = 15), euploid 
females (n = 20), and trisomic females (n = 12) from the 2252
Cryo2010
 cohort. K) Table 
illustrates behaviors that were significantly delayed in 5252
2014
 Ts65Dn mice in prior 
publications (Olmos-Serrano et al., 2016b; Aziz et al., 2018) versus the presently studied 
5252
Cryo2010
 mice. Arrows indicate behaviors that trisomic animals were significantly 







Figure 11. Developmental milestone acquisition by day for males. A-J) Proportion of male 
euploids (n = 20) and trisomics (n = 15) acquiring cliff aversion (A), eye opening (B), ear twitch 
(C), negative geotaxis (D), forelimb grasp (E), rooting (F), air righting (G), auditory startle 
(H), open field (I), and surface righting (J) across all days of testing. Line graphs show 
percentage of animals that acquired the milestone on each specific postnatal day of testing. 
Fischer Exact test was used to determine statistical significance between genotypes at each 
day with a probability level of p < 0.05 considered statistically significant. K) Trisomic 
5252
Cryo2010
 males have a significantly greater cumulative DM score compared to euploids (p 
= 0.0009). Box plot depicts the median ± Q1 and Q3 with individual data points. Unpaired 
two-way Student’s t-test was used to examine cumulative DM score differences with a 
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Figure 12. Developmental milestone acquisition by day for females. A-J) Proportion of 
female euploids (n = 20) and trisomics (n = 12) acquiring cliff aversion (A), eye opening (B), 
ear twitch (C), negative geotaxis (D), forelimb grasp (E), rooting (F), air righting (G), auditory 
startle (H), open field (I), and surface righting (J) across all days of testing. Line graphs show 
percentage of animals that acquired the milestone on each specific postnatal day of testing. 
Fischer Exact test was used to determine statistical significance between genotypes at each day 
with a probability level of p < 0.05 considered statistically significant. K) Trisomic 5252
Cryo2010
 
females have a significantly greater cumulative DM score compared to euploids (p = 0.036). 
Box plot depicts the median ± Q1 and Q3 with individual data points. Unpaired two-way 
Student’s t-test was used to examine cumulative DM score differences with a probability level of 
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 mice show impaired spatial learning on the MWM task. Line 
graphs mean ± SEM of each genotype. Repeated measured 2-way ANOVAs and post hoc 
Sidak multiple comparisons tests were used to compare trisomic performance to controls. Bar 
graph shows mean ± SEM with unpaired two-way Student’s t-test used to assess differences 
between genotypes. A probability level of p < 0.05 considered statistically significant for all 
measures. A) The latency to reach the cued or hidden platform across consecutive days of the 
task was significantly impacted by genotype (n = 24, 24, F1, 46 = 11.28, p = 0.002). B) Latency 
to reach platform was not influenced by sex for trisomic mice (n = 12, 12, F1,22 = 1.11, p > 
0.999). C) Probe trial conducted after the hidden acquisition phase shows time spent in the 
target quadrant with 5252
Cryo2010
 mice spending significantly less time in the target quadrant 
than controls (p = 0.004). D&E) Swimming speed (D) and distance traveled (E) across days 
during the hidden acquisition phase. No effect of genotype on velocity (F1, 46 = 0.006, p = 





Figure 14. Correlation of acquisition of developmental milestones with 
performance on MWM. A&B) Scatter plots of total time spent in target quadrant on 
probe trial versus cumulative DM score for males (A) and females (B). Pearson 
correlation coefficient calculated for each sex shows no relationship between 





Post-natal characterization of the Ts66YAH mouse model of Down syndrome   
Introduction 
Translational research depends upon animal models that demonstrate disease 
relevant, reproducible, and constant phenotypes. This is a particularly sensitive problem 
for the field of Down syndrome research due to the complex genetic nature of the syndrome 
that produces a large range of phenotypes for which severity can vary significantly in the 
patient population. Down syndrome is caused by the triplication of human chromosome 21 
(HSA21) and is characterized by phenotypes that impact many organ systems throughout 
the body including shortened stature, craniofacial abnormalities, delayed motor skill 
acquisition, neuroanatomical changes, cognitive impairments, and early onset Alzheimer’s 
disease pathology (Anatonarakis et al., 2020). The field of Down syndrome research 
utilizes a number of tools that can model gene dosage, aneuploidy, single gene triplications 
or rescues, or a combination of these to study the effects of trisomy 21. However, due to 
the complex genetic landscape of Down syndrome, constructing a mouse model that 
mimics both genetic content and exhibits a large number of disease-relevant phenotypes 
has been difficult.  
 The Ts65Dn mouse model is the oldest model in the field and has been shown to 
recapitulate many phenotypes present in people with Down syndrome. The Ts65Dn model 
has an extra chromosome formed by a reciprocal translocation of the portion of mouse 
chromosome (MMU) 16 that is syntenic to HSA21 onto the centromeric region of MMU17 




research as it has the triplication of over 100 gene orthologs that are also triplicated in 
people with DS as well as an extra chromosome, thus modeling both gene content 
triplication and aneuploidy. Ts65Dn mice show similar deficits to those with Down 
syndrome, such as delayed acquisition of motor skills, poor motor control, and impaired 
spatial learning and memory and working memory (Holtzman et al., 1996; Toso et al., 
2008; Olmos-Serrano et al., 2016b; Aziz et al., 2018; Reeves et al., 1995; Costa et al., 
2010; Stasko and Costa, 2004; Sago et al., 2000; Rueda et al., 2012). One major downfall 
of the Ts65Dn model however, is that the extra chromosome contains a third copy of about 
60 genes from MMU17 that are not DS-related, meaning they are triplicated in the mice 
but not in people with Down syndrome (Duchon et al., 2011; Reinholdt et al., 2011). These 
genes are involved in protein transport/localization, membrane fraction, cytoskeleton, and 
ion binding (Duchon et al., 2011) but it is unclear if the gene dosage imbalance of these 
contribute to the phenotypes present in Ts65Dn.  
 The Ts66YAH model was recently developed and designed to address the concerns 
regarding the non-DS-related genes present in Ts65Dn mice. This model was made using 
crisper mediated rearrangement strategies (CRISMERE), a modified CRISPR/Cas9 system 
(Birling et al., 2017), to remove the MMU17 genes in question from existing Ts65Dn mice. 
The resulting line contains the same genetic composition as Ts65Dn except for the absence 
of the 60 non-DS-related genes. The Ts66YAH provides the field a necessary tool to 
evaluate the effects of gene dosage versus aneuploidy and the role that MMU17 gene 
triplication plays in the phenotypes of Ts65Dn. As this novel model has not yet been 




behavioral phenotypes to determine the similarities between Ts66YAH and Ts65Dn and 
the utility of Ts66YAH as a model for studying Down syndrome.  
Results 
Gross anatomy measurements 
 To determine if the newly developed Ts66YAH mice display anatomical alterations 
previously seen in Ts65Dn we collected body weight of males at P15, P30, and P60 prior 
to sacrifice. Ts66YAH males were significantly smaller than euploid controls at P15 (n = 
11, 4; p = 0.047) but this body weight difference normalized at P30 (n = 5, 8) and P60 (n 
= 8, 5) (Figure 15A).  
 Ts65Dn mice exhibit a microencephaly phenotype, specifically showing a shorter 
rostral-caudal length of the telencephalon (Chapter 1; Holtzman et al., 1996; Hill et al., 
2007; Richtsmeier et al., 2000; Shaw et al., 2020). To identify the presence of this 
phenotype in Ts66YAH animals, we measured the rostral-caudal (R-C) and medial-lateral 
(M-L) lengths of the telencephalon at P15, P30, and P60 (Figure 15B&C). We found that 
Ts66YAH males have a shorter R-C length at P15 (p = 0.046) which normalizes at P30 and 
P60. M-L length was measured as well and showed no difference at P15, P30, nor P60 
(Figure 15C). These results indicate that Ts66YAH males have smaller body and brain 
size early in life but this difference normalizes by adulthood, similar to what was seen in 
our analysis of Ts65Dn (Figure 5).  
 Lastly, individuals with Down syndrome display hypotonia early in life and motor 
impairments that persist into adulthood (Morris et al., 1982; (Malak et al., 2015; Ulrich et 




2020). To determine if Ts66YAH mice show similar motor dysfunction, we measured the 
limb-splay score to quantify the hind limb reflex (Figure 15D). Ts66YAH males had 
normal hindlimb reflexes at P15 and P30 but did show a significantly increased splay score 
at P60 compared to euploid controls (n = 8, 5; p = 0.009). In this metric, Ts66YAH mice 
differ from previous reports of Ts65Dn (Chapter 1; Shaw et al., 2020).   
Hippocampal and cerebellar cell density 
 Individuals with Down syndrome have reduced total hippocampal and cerebellar 
volumes and studies show this is due to a reduction in neuronal density (Guidi et al., 2008; 
Guidi et al., 2011; Pinter et al., 2001; Olson et al., 2007; Winter et al., 2000; Guilhard-
Costa et al., 2006; Golden et al., 1994; Kesslak et al., 1994; Aylward et al., 1997; Aylward 
et al., 1999). These anatomical changes could be a contributing factor to the learning and 
memory impairments and motor dysfunction in Down syndrome. Previous reports in 
Ts65Dn show a marked decrease in cell density in the hippocampus and cerebellum as well 
(Lorenzi & Reeves, 2006; Insausti et al., 1998; Kurt et al., 2004) however, our most recent 
reports do not see this phenotype consistent across all cohorts of Ts65Dn animals (Chapter 
2; Shaw et al., 2020). To determine the presence or absence of a neuronal density decrease 
in Ts66YAH we counted an analyzed the number of NeuN+ cells in CA1 and CA3 regions 
of the hippocampus in P60 males (n = 5 euploid, 5 trisomic). We found that there was no 
significant difference in neuronal density in either region when compared to euploid 
controls (Figure 16A).  In a similar way, we counted the NeuN+ cells in Lobule III and 
IV/V of the cerebellum. When normalized to euploid controls, there was no significant 




n = 4 euploid, 5 trisomic). Our findings show that Ts66YAH animals do not have a cell 
density phenotype as seen in people with Down syndrome and some cohorts of Ts65Dn 
mice.   
Maturation of oligodendrocytes and myelin formation 
 Oligodendrocyte development and myelin formation have been shown to be 
perturbed in both people with Down syndrome as well as Ts65Dn (Wisniewski and 
Schmidt-Sidor, 1989; Dambaska and Laure-Kaminonwska, 1990; Ábrahám et al., 2010; 
Olmos-Serrano et al., 2016a). To measure these phenotypes in Ts66YAH animals, we 
counted the mature oligodendrocyte population (CC1+/Ng2-/Olig2+) in the corpus 
callosum of euploid and trisomic Ts66YAH males at P15 (n = 5, 4), P30 (n = 5, 5), and 
P60 (n = 5, 5) and found no significant difference in percentage of mature oligodendrocytes 
at any age (Figure 17A). Although number of mature oligodendrocytes was not altered in 
trisomic animals compared to euploid controls, the ability of those cells to produce myelin 
could be affected. We performed RT-qPCR on tissue from the corpus callosum and cortex 
of P30 males (n = 5, 5) for myelin-related genes MAG (myelin-associated glycoprotein) 
and MBP (myelin basic protein) and found no difference in expression when compared to 
euploid controls (Figure 17B). Taken together, these findings indicate that unlike people 
with Down syndrome and some Ts65Dn animals, Ts66YAH mice do not display altered 
oligodendrocyte maturation or myelin formation.  
Acquisition of developmental milestones in Ts66YAH 
 The development of fine and gross motor skills is delayed in individuals with Down 




Hartley, 1986; Matson et al., 2010; Ulrich et al., 2001; Horovitz and Matson, 2011; 
Cardoso et al., 2015) and this trait is also seen in Ts65Dn pups (Holtzman et al., 1996; 
Toso et al., 2008; Olmos-Serrano et al., 2016b; Aziz et al., 2018; Shaw et al., 2020). To 
compare early life motor and sensory skill development of Ts66YAH animals, we 
measured the acquisition of ten developmental milestones in males (n = 13 euploid, 10 
trisomic) and females (n = 20 euploid, 6 trisomic) (Figures 18, 19, 20). Of the ten tasks, 
only three tasks were acquired at different ages compared to euploid controls; Ts66YAH 
trisomic males acquired the auditory startle reflex significantly earlier than euploid controls 
(Figure 18J; p = 0.043). Ts66YAH trisomic females were significantly delayed in 
acquiring cliff aversion (p = 0.034) but on average, opened their eyes significantly earlier 
than euploid controls (Figures 18C,F, p = 0.048). This differs from our findings with 
Ts65Dn animals (Chapter 4, Figure 10), which shows males are significantly delayed in 
eye opening, ear twitch, negative geotaxis, open field, and surface righting acquisition 
suggesting that Ts66YAH animals do not replicate the Ts65Dn phenotypes or recapitulate 
the human characteristic of delayed motor and sensory skill development.  
 To quantify overall developmental on these tasks, we calculated the DM score for 
Ts66YAH which normalizes age of acquisition for each task on a ten-point scale and the 
sum of these values represents an individual subject’s developmental score. Euploid males 
and Ts66YAH males did not significantly differ in their composite DM scores (Figure 
19K) nor did females (Figure 20K). Taken together, this data suggests that Ts66YAH 
mice, unlike Ts65Dn, are not delayed in their acquisition of early life motor skills.  




 Cognitive impairment is present in most cases of Down syndrome with spatial 
learning and memory specifically being affected (Lavenex et al., 2015; Marcell and 
Armstrong, 1982; Jarrold et al., 2006). Ts65Dn mice show similar impairments measured 
with the Morris water maze. Trisomic mice take longer to find the location of a hidden 
platform based on spatial cues (Chapter 4, Figure 13; Reeves et al., 1995; Costa et al., 
2010; Shaw et al., 2020) and are unable to relearn the platform location during a reversal 
phase (Olmos-Serrano et al., 2016b). To determine the learning and memory capabilities 
in Ts66YAH animals, we tested male Ts66YAH and euploid controls in the Morris water 
maze with reversal phase (Figure 21). Both genotypes successfully learned the location of 
the cued platform and showed no difference in swimming speed (Figure 21D; n = 13, 10, 
F1,67 = 2.280, p = 0.136) or distance swam (Figure 21E; n = 13, 10, F1,67 = 0.536, p = 0.467) 
across days, indicating no difference in physical ability to perform the task. 
Latency to reach the hidden platform decreased for both genotypes across days (n 
= 13, 10, F11,230 = 6.646, p < 0.0001) and there was no difference in latency between 
genotypes (n = 13, 10, F1,21 = 0.106, p = 0.748). This learning is quantified during a probe 
trial with results showing no significant difference between genotypes in time spent in 
target quadrant (Figure 21B) suggesting both groups effectively learned the location of the 
hidden platform.  
Similar results were found during the reversal phase training. Euploid and trisomic 
males both decreased latency to the reversal platform across days (F3,63 = 17.85, p < 0.001) 
with no significant impact of genotype (F1,21 = 0.675, p = 0.421). Again, this was quantified 




genotypes (Figure 21C). Taken together, these results suggest that Ts66YAH males do not 
display learning and memory deficits when tested using the Morris water maze. 
Correlation of DM score and adult learning and memory performance 
 Early life development can be useful predictors of cognitive outcomes during 
adolescence and adulthood. Studies with Ts65Dn show that DM score is predictive of 
Morris water maze performance, with higher cumulative DM scores being associated with 
longer latencies to reach the hidden platform (Olmos-Serrano et al., 2016b). To determine 
if developmental milestones are predictive of adult behaviors for Ts66YAH mice, we 
compared the total time spent in the target quadrant during either the hidden or reversal 
phase to the composite DM score for each male animal. We found no correlation between 
DM score and Morris water maze performance on either the hidden (Figure 22A; r = -0.03, 
p = 0.892) or the reversal (Figure 22B; r = -0.07, p = 0.751) phase.  
Discussion 
 Our comprehensive, comparative analysis of the Ts66YAH mouse model of Down 
syndrome shows minor anatomical changes in trisomic mice when measuring body weight 
and brain size. There are no differences in cellular density in the hippocampus or 
cerebellum between trisomic and euploid mice. Likewise, we see no alterations to the 
maturation profile of oligodendrocytes. Additionally, Ts66YAH mice do not exhibit 
deficits in the acquisition of early life developmental milestones or adult learning and 
memory performance on the MWM. Taken together, these results indicate that the 
Ts66YAH model does not reflect the cellular and behavioral abnormalities previously 




 Although the Ts66YAH model closely resembles the genetic composition of 
Ts65Dn, the removal of the 60 non-DS-related genes could account for the reduced 
phenotypic severity in Ts66YAH. A number of the genes triplicated from the centromeric 
region of MMU17 are involved in processes that could affect the phenotypes being 
measured. For example, Tiam1 and Tiam2 are involved in neuronal outgrowth and the 
construction of synapses, especially within the hippocampus (Terawaki et al., 2010; Rao 
et al., 2019) and altered expression of Tiam1 can result in changes to the brain during 
embryonic development (Yoo et al., 2012). Tiam1 is located within the syntenic portion of 
MMU16 and triplicated in Ts65Dn as well as people with Down syndrome. Tiam2 however 
is on MMU17 and is triplicated in Ts65Dn mice but not in people with DS. Likewise, the 
Ts66YAH model does not contain the MMU17 non-DS-related genes and therefore has 
three copies of Tiam1 and normal expression of Tiam2. It is possible that the abundant 
overexpression of both Tiam1 and Tiam2 in Ts65Dn exacerbates the neurological 
phenotypes seen in those mice. Whereas, the normalized gene dosage of Tiam2 in the 
Ts66YAH model may contribute to the lack of learning and memory deficits seen in MWM 
performance.  
In a similar way, ARID1B is a chromatin-remodeling gene that regulates dendritic 
arborization and spine development in pyramidal neurons (Ka et al., 2016). Mutations in 
ARID1B can cause a developmental disorder, Coffin-Siris syndrome, which is 
characterized by intellectual disability (Tsurusaki et al., 2012; Santen et al., 2012). Like 
Tiam2, ARIB1B is located on MMU17 and triplicated in Ts65Dn but not in Ts66YAH mice 




cognitive deficits seen in that model but not in Ts66YAH, resulting in reduced phenotypic 
severity. These examples illustrate how the triplication of genes from MMU17 that are not 
relevant to DS could worsen the phenotypes seen in Ts65Dn and how the normalized 
expression of those genes in Ts66YAH could underlie the rescue of both anatomical and 
behavioral phenotypes.  
 Another factor that could impact the characteristics of Ts66YAH mice is the 
phenotypic makeup of the Ts65Dn cohort that was originally used in generating the 
Ts66YAH line as these animals were produced by genetically modifying existing Ts65Dn 
mice. Phenotype presence and severity differs between generations of Ts65Dn (Shaw et 
al., 2020), therefore, if the cohort of Ts65Dn selected to make Ts66YAH did not have a 
significant phenotypic deficit, the resulting Ts66YAH line may not either, regardless of 
whether the non-DS-related genes are triplicated or not. To further investigate this as a 
contributing factor, a comparative study between the Ts66YAH line and the generational 
cohort of Ts65Dn they stemmed from is necessary.  
 The field of Down syndrome research has a number of mouse models available that 
represent various components of Down syndrome, with one of the most popular models 
being Ts65Dn. While Ts65Dn has many traits in common with Down syndrome, the 
genetic makeup of the model has always been a concern. Ts66YAH was designed to 
address these problems and provide a more refined platform with which we can study the 
underlying mechanisms of and possible therapeutics for DS. However, our in depth 




it does not demonstrate the neurological and behavioral alterations that mimic those seen 




F igure 15. Gross anatomical measurements of Ts66YAH. Boxplots show median value ± Q1 & Q3 with individual data points. Bar graphs display mean ± SEM. All comparisons are   
unpaired two-way Student’s t-test between trisomic and euploid controls at each age with a 
probability level of p < 0.05 considered statistically significant. A) Body weight 
m easurements show Ts66YAH males are significantly smaller than euploid controls at P15 (n = 11, 4; p = 0.047) but not at P30 (n = 5, 8) nor P60 (n = 8, 5). B) Ts66YAH rostral-
c audal length is significantly shorter at P15 (n = 11, 4; p = 0.046) but no difference at P30 (n = 6, 8) or P60 (n = 8, 5). C) Measurement of the medial-lateral length shows no change 
at  P15 (n = 11, 4), P30 (n = 6, 8), or P60 (n = 8, 5) between genotypes. D) Hind-limb reflex measured at P15 (n = 11, 4), P30 (n = 6, 8), and P60 (n = 8, 5) show a significantly larger 










Figure 16. Cell densities within hippocampal and cerebellar regions of 
Ts66YAH. Boxplots show median value ± Q1 & Q3 with individual data points. 
Comparisons are unpaired two-way Student’s t-test between trisomic and euploid 
controls with a probability level of p < 0.05 considered statistically significant. A) 
NeuN+ cell density in the CA1 and CA3 regions of the hippocampus normalized 
to euploid controls, presented as percent of euploid (n = 5 euploid, 5 trisomic). B) 
Density of NeuN+ cells in Lobule II and IV/V of the cerebellum show no 
difference in neuronal density when compared to euploid controls (n = 5 euploid, 
5 trisomic).  
97 
Figure 17. Maturation of oligodendrocyte lineage and myelin formation in 
Ts66YAH. Boxplots show median value ± Q1 & Q3 with individual data 
points. Bar graphs display mean ± SEM. All comparisons are unpaired two-
way Student’s t-test between trisomic and euploid controls with a probability 
level of p < 0.05 considered statistically significant. A) Percentage of mature 
CC1-expressing oligodendrocytes in the corpus callosum of Ts66YAH males 
and euploid controls at P15 (n = 5, 4), P30 (n = 5, 5), and P60 (n = 5, 5) with 
no statistical change between genotypes at any age. B) Expression of myelin-
related genes MAG and MBP in trisomic animals normalized to relative 
expression levels in Ts66YAH males at P30 in the corpus callosum and cortex 






Figure 18. Developmental milestone acquisition in Ts66YAH. Boxplots show 
median value ± Q1 & Q3 with individual data points. All comparisons are unpaired 
two-way Student’s t-test between trisomic and same-sex euploid controls with a 
probability level of p < 0.05 considered statistically significant. A-J) Boxplots 
showing the average day of acquisition for developmental milestones for euploid 
males (n = 13), Ts66YAH males (n = 10), euploid females (n = 20), and Ts66YAH 




Figure 19. Developmental milestone acquisition by day for male Ts66YAH mice. A–J) 
Proportion of male euploids (n = 13) and trisomics (n = 10) acquiring surface righting (A), rooting 
(B), cliff aversion (C), negative geotaxis (D) open field (E), eye opening (F), ear twitch (G), air 
righting (H), forelimb grip (I), and auditory startle (J) across all days of testing. Line graphs show 
percentage of animals that acquired the milestone on each specific postnatal day of testing. Fischer 
Exact test was used to determine statistical significance between genotypes at each day with a 
probability level of p < 0.05 considered statistically significant. K) Average cumulative DM score 
for euploids and Ts66YAH males are not significantly different. Box plot depicts the median ± Q1 
and Q3 with individual data points. Unpaired two-way Student’s t-test was used to examine 
cumulative DM score differences with a probability level of p < 0.05 considered statistically 
significant. 
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Figure 19. Developmental milestone acquisition by day for male Ts66YAH mice. A-J) Proportion of 
male euploids (n = 13) and trisomics (n = 10) acquiring surface righting (A), rooting (B), cliff aversion (C), 
negative geotaxis (D) open field (E), eye opening (F), ear twitch (G), air righting (H), forelimb grip (I), and 
auditory startle (J) across all days of testing. Line graphs show percentage of animals that acquired the 
milestone on each specific postnatal day of testing. Fischer Exact test was used to determine statistical 
significance between genotypes at each day with a probability level of p < 0.05 considered statistically 
significant. K) Average cumulative DM score for euploids and Ts66YAH males are not significantly 
different. Box plot depicts the median ± Q1 and Q3 with individual data points. Unpaired two-way Student’s 






Figure 20. Developmental milestone acquisition by day for female Ts66YAH mice. A-J) 
Proportion of female euploids (n = 20) and trisomics (n = 6) acquiring surface righting (A), 
rooting (B), cliff aversion (C), negative geotaxis (D) open field (E), eye opening (F), ear twitch 
(G), air righting (H), forelimb grip (I), and auditory startle (J) across all days of testing. Line 
graphs show percentage of animals that acquired the milestone on each specific postnatal day 
of testing. Fischer Exact test was used to determine statistical significance between genotypes 
at each day with a probability level of p < 0.05 considered statistically significant. K) Average 
cumulative DM score for euploids and Ts66YAH females are not significantly different. Box 
plot depicts the median ± Q1 and Q3 with individual data points. Unpaired two-way Student’s 
t-test was used to examine cumulative DM score differences with a probability level of p < 





Figure 21. Morris water maze testing reveals no difference in learning and memory in 
Ts66YAH males. Line graphs mean ± SEM of each genotype. Repeated measured 2-way 
ANOVAs and post hoc Sidak multiple comparisons tests were used to compare trisomic 
performance to controls (A, D, E). Bar graph shows mean ± SEM with unpaired two-way 
Student’s t-test used to assess differences between genotypes (B & C). A probability level of 
p < 0.05 considered statistically significant for all measures. A) The latency to reach the 
platform across consecutive days of the hidden and reversal phases decreased for both 
genotypes (n = 13, 10, F11,230 = 6.646, p < 0.0001; F3,63 = 17.85, p < 0.001) but was not 
significantly impacted by genotype (n = 13, 10, F1,21 = 0.106, p = 0.748; F1,21 = 0.675, p = 
0.421). B&C) Probe trials conducted after the hidden acquisition phase (B) and reversal 
probe (C) shows percentage of time spent in the target quadrant with no difference between 
euploid and trisomic Ts66YAH mice. D&E) Swimming speed (D) and distance traveled (E) 
across days during the hidden acquisition phase. No effect of genotype on velocity (F1, 67 = 







Figure 22. Correlation of developmental milestone acquisition and performance 
on MWM for Ts66YAH mice. A&B) Scatter plots of total time spent in target quadrant 
on hidden probe trial (A) or reversal probe trial (B) versus cumulative DM score for 
males. Pearson correlation coefficient calculated for each shows no association between 





Validity of phenotypes in the Ts65Dn mouse model  
Animal models are valuable tools in translational and preclinical research. 
However, for these models to be used effectively, they must be comprehensively validated 
to ensure reproducible and disease-relevant findings that are consistent across time. The 
Ts65Dn model has been shown to recapitulate many of the phenotypes present in people 
with Down syndrome but the stability of those phenotypes has never been addressed. Our 
evaluation here demonstrates that the Ts65Dn mouse model of DS is variable both on a 
subject-to-subject basis as well as across generational breeding cohorts (Figure 23, Table 
2) making comparisons across time and labs difficult, and slowing progress in identifying 
the underlying cellular and molecular causes of DS. In this study we highlight several well-
characterized neurological phenotypes, relevant to the formulation and testing of 
preclinical studies, which are subject to phenotypic variability over time. This variability 
consists of the disappearance and appearance of various phenotypes in different Ts65Dn 
cohorts. 
Phenotypic variation in the Ts65Dn colony could be due to a number of factors, 
making it a complicated and multifaceted concern to address. Variability seen within a 
Ts65Dn cohort could be attributable to genetic differences between animals due to their 
hybrid background. Additionally, these genetic differences may lead to variability between 
cohorts, creating “mini-colonies” of animals due to selective breeding practices that utilize 
dams with higher litter success rates. These two factors may be occurring in labs breeding 




factor contributing to phenotypic variability and drift over time is the possibility of genetic 
variations leading to natural evolution occurring in the Ts65Dn line as a whole. Consistent 
large-scale breeding of this line of animals over time could have resulted in a gradual 
change of Ts65Dn such that animals being studied currently are no longer the same as the 
version of Ts65Dn that was originally developed and characterized. The data presented in 
this study provide examples of how these individual factors are contributing to the variance 
and phenotypic changes seen in Ts65Dn. 
Genetic variability  
One critical factor behind much of this phenotypic variance may be the genetic 
variability in these animals. Early in the development of Ts65Dn, it was discovered that 
the line would cease to generate trisomic offspring if kept on a strict inbred C57BL/6JEiJ 
background (Davisson and Costa, 1999). Thus, routine breeding to maintain the colony, 
both at Jackson Laboratory and in investigator labs, consists of crossing a trisomic Ts65Dn 
dam to an F1 hybrid male (B6EiC3H), which is the first-generation offspring from a cross 
between a C57BL/6JEi and a C3Sn.BLiA-Pde6b+/DnJ (Figure 3). As F1 hybrid 
(B6EiC3H) mice are a cross of two different inbred strains, they are expected to be 
heterozygous at all loci for which the parental lines differ. Although all F1 hybrids are 
assumed to be genetically and phenotypically the same, the B6EiC3H line is not inbred and 
therefore subject to genetic variations that may impact phenotypes. In fact, even inbred 
sub-strains of B6 mice, bred into closed colonies, show behavioral differences (Bryant et 




In addition to inherent genetic variability between potential sub-strains of F1 
hybrids, variations in allelic segregation during gametogenesis mean the particular allelic 
combination passed to offspring may vary across litters, and even between littermates. 
Ts65Dn mice on average carry half B6 and half C3H alleles, however, individual mice can 
be homozygous or heterozygous for either allele at all loci. Therefore, each cross between 
an F1 hybrid and trisomic female results in a different admixture of alleles across the 
genome in each offspring. Additionally, as female Ts65Dn within a colony are 
continuously backcrossed to the F1 hybrid males, the allelic combination the dams have 
inherited and then pass on to their offspring is not consistent across animals either, further 
complicating the genetic makeup of the Ts65Dn animals.  
 This genetic variance may have significant consequences on the phenotypic output 
of each animal, thus creating a wide range of phenotypic severity seen in any given cohort. 
For example, the allelic diversity could explain the variability seen in the developmental 
milestones. In our analysis of 5252Cryo2010 mice, we found that trisomic mice are delayed in 
their overall early post-natal development (DM scores) (Chapter 4; Figures 11K, 12K) but 
analysis of variance within each genotype (Table 1) uncovers striking variability in the 
trisomic populations. For eight of the ten milestones, male trisomic 5252Cryo2010 mice show 
a larger variance score compared to euploid controls, indicating that the trisomic mice have 
a more broad range of acquisition age. A similar range of variance is also seen in 
measurements of brain anatomy at post-natal stages (Chapter 1; Figure 5). This range in 
measurements, seen specifically in the trisomic animals, could be due to genetic differences 




population is heterogeneous, even within a single cohort of animals, perhaps due to the 
genetic differences induced by F1 hybrid genetic background and allelic diversity.  
Studies have shown that the background on which a trisomic animal is bred can 
influence the phenotypic characterization of the animals (Deitz and Roper, 2011, Roper et 
al., 2020). The Ts1Rhr mouse model is trisomic for ~33 gene orthologs that are present in 
the DSCR on HSA21 (Olson et al., 2004). When Ts1Rhr mice are bred on a complete B6 
background, trisomic mice have no change in LTP or learning and memory on the MWM 
(Olson et al., 2007; Dietz and Roper, 2011). However, when maintained on the B6EiC3H 
F1 hybrid background, trisomic mice display larger body and brain size compared to 
euploid controls but have decreased LTP and impaired performance on object recognition 
tasks (Belichenko et al., 2009; Dietz and Roper, 2011). Lastly, when on a mixed 
background of B6, C3H, and 129S1 trisomic mice have larger body sizes than euploid 
controls but smaller brain and cerebellum sizes (Roper et al., 2009). This evidence further 
suggests that the complex genetic landscape of trisomic mice is highly susceptible to allelic 
differences in backgrounds that affect phenotypes.  
This is similar to what is seen in people with Down syndrome where individuals 
display a subset of characterized traits but to variable degrees of severity. This may be due 
to allelic differences in the triplicated genes, as well as in the non-trisomic genes. Trisomy 
21 alters gene expression across the genome (Vilardell et al., 2011; Olmos-Serrano et al., 
2016a; Letourneau et al., 2014; Mao et al., 2003, 2005; Lockstone et al., 2007) and thus, 
allelic variations that result in altered expression of a single gene can either directly alter 




involved in particular phenotypes. Additionally, aneuploidy may sensitize the effect of 
different allelic combinations (Roper et al., 2020; Li et al., 2012). For example, individuals 
with Down syndrome are prone to having congenital cardiac defects (CHD) (Ferencz et 
al., 1989). However, this occurs in only 40-50% of people with DS (Freeman et al., 2008), 
suggesting trisomy 21 alone is not sufficient to cause CHD and variations at non-triplicated 
loci may contribute to the presence of heart defects. Atrioventricular septal defects (AVSD) 
are among the more severe heart abnormalities and are associated with mutations in 
CRELD1 however, these mutations alone are not necessary nor sufficient to cause AVSD 
(Robinson et al., 2003; Maslen et al., 2004, 2006). Studies have suggested a “threshold 
hypothesis” could contribute; When CRELD1 mutations are present in a trisomic 
environment, these typically benign variants act as genetic modifiers to combine with 
trisomic genes in an additive manner to produce AVSD in people with Down syndrome 
(Li et al., 2012). The effect of allelic variants across the genome may work in concert with 
trisomy 21 to produce more severe phenotypes in some individuals. Likewise, in Ts65Dn, 
although they are supposed to be genetically similar, the particular background strain and 
allelic combination may impart increased genetic diversity that can influence phenotypes 
of individual animals.   
To further complicate the genetic state of the Ts65Dn line, there are the potential 
genetic differences between the 1924 and 5252 strains that could account for phenotypic 
inconsistencies between the two sub-strains of Ts65Dn. The 1924 line was originally 
generated from DBA/2J mice and bred on a C57BL/6J background for a short time before 




The F1 hybrid background that 1924 was maintained on contained a mutation in the Pde6b 
allele, carried by the C3H line, which caused retinal degeneration (Keeleer, 1924). This 
mutation was corrected for by backcrossing animals carrying the wildtype allele with 
C3H/HeSnJ animals (Costa et al., 2010). The 5252 strain of Ts65Dn is bred on the Pde6b-
corrected background and is separately maintained from the 1924 line. While the resulting 
5252 line is congenic to 1924, only differing in the presence of the Pde6brd1 mutation, 
repeated backcrossing can result in the passage of other alleles that are required for 
increased survival or reproduction (Montagutelli, 2000). These “passenger loci” may differ 
between the congenic lines and could produce phenotypic differences between 1924 and 
5252 Ts65Dn mice (Lusis et al., 2007; Roper et al., 2020).   
Breeding strategies   
Another explanation for the discordant phenotypes in Ts65Dn animals may be the 
colony maintenance and breeding practices that can inadvertently generate sub-colonies of 
Ts65Dn. Generally, labs studying Ts65Dn will acquire breeding founders which can then 
be used to expand and maintain their personal colonies. Only female Ts65Dn mice are 
fertile, therefore the propagation of the line depends on the successful breeding of trisomic 
females. The long-term maintenance and in-house production of Ts65Dn has always been 
a difficulty as litter size tends to be small, there is prenatal and perinatal loss of trisomic 
pups, and the trisomic dams often do not provide adequate maternal care for newborn litters 
(Roper et al., 2005). Thus, females that have high success rates with breeding and litter 




variability present in the dams, genetic changes associated with increased breeding fitness 
may be correlated with improvement in other phenotypes seen in offspring. 
If the genetic variables influencing maternal care are associated with reduced 
phenotypic severity in the offspring, this could lead to a predominance of litters having 
altered or reduced phenotypic profiles. Eventually, if this type of selective breeding persists 
over generations, it could generate “mini-colonies” of Ts65Dn in individual laboratories 
with unique phenotypic makeups. This may explain why dramatic shifts in phenotypes are 
observed in our report here when new breeding females are imported from Jackson 
Laboratories, causing a disruption in the cycle of selective breeding. For example, when 
measuring the oligodendrocyte maturation phenotype, original data from Olmos-Serrano 
et al. (2016) identified a decrease in the percentage of mature oligodendrocytes in Ts65Dn 
animals bred in-house between the years 2012-2014. However, when our laboratory 
measured the same phenotype with the same methodology but from two separate sets of 
breeding dams (5252Cryo2010 and 52522015) these other cohorts did not exhibit alterations in 
the population of mature oligodendrocytes. However, a more recent cohort (52522019) did 
have a significantly reduced percentage of mature oligodendrocytes in the corpus callosum 
(Chapter 3; Figures 8, 23).  
If increased breeding fitness and maternal care are correlated with improved 
development of offspring, over generations of large-scale breeding, the once present 
phenotypes, such as body and brain size reduction, may be diluted from the population as 
a whole. This selective breeding and drift phenomenon may explain the gradual lessening 




show a severe decrease in body and brain size, both embryonically and across the postnatal 
lifespan (Roper et al., 2006; Bianchi et al., 2010; Costa et al., 2010), while 5252Cryo2010 
exhibit a more minor phenotype and Ts65Dn animals bred and measured generations apart 
(52522019 ) do not display any reduction in gross brain size (Chapter 1; Figure 5; Shaw et 
al, 2020). Similar findings have been seen in the characterization of embryonic brain 
development across the Ts65Dn line. Ts65Dn animals of the 1924 strain had well 
documented decreases in pallial thickness during embryonic development when previously 
studied in 2007 (Chakrabarti et al., 2007). However, when this phenotype was measured 
in more recent 1924 mice in 2017 there was no longer a significant decrease (Shaw et al, 
2020). The same trend was found in the 5252 line where embryos from the 5252Cryo2010 era 
show a significantly reduced pallial thickness at E14.5 compared to controls while trisomic 
embryos from years later in the 52522014 cohort show no difference (Shaw et al., 2020). 
Lastly, trisomic fetuses from 52522019 have a significant increase in pallial thickness 
compared to their controls (Shaw et al., 2020). These examples demonstrate the shifting of 
phenotypes over the course of Ts65Dn breeding history. While the studies presented in this 
report may accurately represent the phenotypes of any given cohort of animals, the 
observed variability, both within and across cohorts, makes data reproducibility a 
challenge. As even within the same laboratory, the dams producing litters may be different, 
genetically and phenotypically. As laboratories seed Ts65Dn colonies from different 
founder animals and maintain their own colonies of Ts65Dn animals in-house for variable 
periods of time, it is likely that their animals now differ dramatically from other 




These present findings uncover major difficulties for the field in using Ts65Dn if 
the line as a whole is evolving to exhibit less severe phenotypes over time and if each 
cohort of mice, and even each mouse, may need to be treated as an individual. While this 
is problematic, in some ways it may be more closely mirroring what is happening in people. 
People with Down syndrome do not have the same baseline genetics and not all have the 
same set or severity of phenotypes. The differences within and between cohorts of animals 
presented here might therefore be considered a representation of the high degree of 
variability that is inherent to Down syndrome. It is possible that Ts65Dn may be accurately 
modeling the population diversity seen in people with Down syndrome. Although this may 
be useful in some instances, studying mice as individual case studies of a human condition 
is not pragmatic and for this reason, we must address this problem and establish a 
responsible way to use Ts65Dn and draw conclusions from these animals. 
Ts66YAH as a model of Down syndrome  
Although Ts65Dn has been the most widely used mouse model of Down syndrome, 
there are many aspects that confound its use. One of the most problematic is the triplication 
of non-DS-related genes. Ts65Dn carries a freely segregating chromosome composed of 
the HSA21 syntenic portion of MMU16 translocated onto the centromeric region of 
MMU17. This extra chromosome contains a third copy of ~104 genes that are triplicated 
in Down syndrome as well as ~60 genes from MMU17 that are not implicated in DS 
(Figure 2C; Davisson et al., 1990, 1993; Duchon et al., 2011; Reinholdt et al., 2011). The 
effect of these non-DS-related genes on the phenotypes seen in Ts65Dn mice has rarely 




The Ts66YAH mouse model was constructed to address this question by targeting 
the removal of the triplicated genes from MMU17 in Ts65Dn animals (Birling et al., 2017). 
The resulting Ts66YAH model is genetically similar to Ts65Dn, except for the absence of 
the non-DS-related genes from MMU17. These mice have not been phenotypically 
characterized before thus, our studies presented here represent the first comprehensive 
postnatal assessment of Ts66YAH mice. Our results show that Ts66YAH trisomic animals 
have no major changes to gross anatomical body or brain size, normal neuronal densities 
in the hippocampus and cerebellum, and no abnormal maturation profile of 
oligodendrocytes. Importantly, they do not display delays in motor and sensory 
development or learning and memory impairments, as previously seen in Ts65Dn. The 
absence of phenotypes in Ts66YAH mice could be due to many of the same factors that 
impact the phenotypic profile of Ts65Dn mice. Ts66YAH is maintained on the F1 hybrid 
and thus subject to the same genetic variables that may be affecting Ts65Dn. Also, as 
Ts66YAH was generated from existing Ts65Dn animals, the particular genetic and 
phenotypic makeup of the founding Ts65Dn animals could skew the characteristics of the 
Ts66YAH line. With the recent recovery of the 5252 line from previously frozen stocks 
(5252Cryo2010), the same genetic manipulation strategies could be used to generate a 
Ts66YAH line that originates from 5252Cryo2010 animals. This would allow for a more direct 
comparison of cohorts to determine if the lack of phenotypes in Ts66YAH mice is due to 
the removal of the ~60 genes, or if it is due to the phenotypic composition of the Ts65Dn 




The lack of phenotypes in Ts66YAH could also be attributed to the removal of the 
non-DS-related genes. As this is the major difference between the two strains, our in-depth 
comparative analysis of the Ts66YAH and Ts65Dn models provides evidence that the DS-
like phenotypes in Ts65Dn are due to the triplication of the MMU17 non-DS-related genes, 
and not directly related to trisomy 21 itself, thus further limiting the use of Ts65Dn in 
Down syndrome research. Although Ts66YAH is a more genetically representative model 
of DS compared to Ts65Dn, trisomic mice on this strain do no display disease-relevant 
neurological phenotypes, making it an inappropriate platform with which to study the 
underlying mechanisms contributing the main features of Down syndrome. 
Future use and impact of mouse models for Down syndrome research  
We urge the community to exercise caution and transparency when conducting 
research with Ts65Dn, Ts66YAH, and other mouse models of Down syndrome. The 
ARRIVE guidelines (Animals in Research: Reporting In Vivo Experiments) (Kilkenny et 
al., 2010) provide a comprehensive set of suggestions to which all research using animal 
models should conform, especially with respect to publishing results. These include 
providing detailed reports of the study design, clear identification of experimental animals, 
husbandry practices, and statistical methods. Based on the results in this report, we propose 
the following additional considerations for research using Ts65Dn and other trisomic 
models of Down syndrome. First, it is important to keep careful animal husbandry practices 
and documentation of parental lineage, litter size, and percentage of trisomic offspring 
produced during the expansion of any colony. In conjunction with that, publications should 




strains, when and from where the lines were acquired, the length of time the colony has 
been propagated in a given laboratory, and the number of founding breeders and F1 animals 
used in colony production and maintenance. Breeding schemes should have a sufficient 
number of trisomic dams in the colony to ensure proper diversity and avoid selective 
breeding. This will make comparisons of data more consistent across laboratories over time 
and ensure more readily reproducible findings. 
Secondly, great care is required when it comes to handling trisomic animals and 
conducting behavioral studies. Some models of DS have an increased sensitivity to 
stressful or anxiety-provoking environments (Stasko and Costa, 2004). In these situations, 
several factors such as number of mice in cages, light and noise intensity in the 
experimental arenas, or experimenter handling must be controlled. In many cases, all 
behavior for both euploids and trisomic animals should be conducted simultaneously to 
avoid any changing factors that could influence results and avoid pooling data from 
multiple sets of behavioral experiments. If this is not possible, publications should indicate 
the number of behavioral cohorts used to generate the sample size for a task. Additionally, 
reports must clearly state whether males and females were used, and how many of each 
were included in the study. If a sex difference is found, each sex should be analyzed 
separately in reference to the respective controls. In terms of data analysis, the statistical 
method used must be appropriate for the question being asked. Sample size or the number 
of litters the mice were derived from should be stated, when possible. With the high degree 
of variance found in Ts65Dn animals here, sample size can dramatically affect results and 




housing and care may vary across facilities. The number of animals per cage and nutritional 
content or batch contaminants in the chow can influence rodent behavior and should be 
noted when possible in publications.  
Lastly, the field must carefully consider the questions the Ts65Dn and Ts66YAH 
mouse models can reliably answer and identify a common path forward if research is to 
continue using these models. This may include more tightly monitoring the genetic 
diversity of these animals and the development of a thresholding system to determine the 
severity of phenotypes in each animal before they enter a study. In addition to phenotype 
thresholding, complimentary models should be implemented when possible. This could 
include the use of multiple mouse models of Down syndrome to confirm a phenotype or 
iPS cells to compare molecular and cellular phenotypes.  However, it is critical to bear in 
mind that all phenotypes being studied in model systems are only relevant if also present 
in people with Down syndrome. When feasible, research utilizing models of Down 
syndrome should be accompanied by human data to validate the findings in mice or in 
cells. 
The Ts65Dn mouse model has been a cornerstone of the Down syndrome research 
field, providing novel and important findings about the genetic and molecular 
underpinnings of trisomy 21 as well as providing a potential platform for pre-clinical Down 
syndrome research. However, our current results show that from generation to generation, 
within the same stock of Ts65Dn, the presence or severity of a phenotype is subject to 
change and the complex genetic makeup of the Ts65Dn line confound the use of it as a 




also make this model unsuitable for studying Down syndrome. Disease models must mirror 
common characteristics of the human condition to be useful and informative. It is important 
for trisomic mice of any model to consistently display DS-like behavioral and 
neuroanatomical abnormalities in order to have a measureable readout when testing 
preclinical treatments and evaluating their potential to help people with Down syndrome 

































Figure 23. Illustrative representation of postnatal Ts65Dn phenotypes across 
time. Illustration represents the change of measured phenotypes across various 
cohorts of Ts65Dn with thicker line widths indicating more severe phenotypes while 
thinner lines represent minimal or no phenotype present. Blank spaces indicate 
phenotype was not measured in that cohort.   
*Summary of previous findings in 1924 line (Reeves et al. 1995; Sago et al. 2004; Roper et al. 2006; Bianchi 
et al. 2010; Lorenzi & Reeves 2006; Baxter et al. 2000; Toso et al. 2008; Holtzman et al. 1996) 





Table 2. Summary of postnatal phenotypes. Table shows summary of findings from postnatal 
characterization of Ts65Dn↓ indicating a decrease or delay, ↑ indicating increase or 
improvement, and – indicating no difference between trisomic and euploid controls.  
*Summary of previous findings in 1924 line (Reeves et al. 1995; Sago et al. 2004; Roper et al. 2006; Bianchi et al. 2010; 
Lorenzi & Reeves 2006; Baxter et al. 2000; Toso et al. 2008; Holtzman et al. 1996) 
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